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Metabolism of medium-chain fatty acids (MCFA) is considered to be independent of carnitine 
because of their passive diffusion into the mitochondrion. However, upon feeding medium-chain 
triglycerides (MCT) to piglets (n=16) followed by serial blood sampling, we observed signifi-
cant changes in free and acyl-carnitines in plasma as determined using a newly developed HPLC 
procedure which allows for quantification of individual carnitine esters. The most noticeably 
change was observed in propionyl-carnitine, which increased significantly (from 0 to 4/*M, 
p<.05) upon feeding odd-chain MCT, while it was undetectable when even-chain MCT were 
fed. This suggests a role for carnitine, likely mediated via buffering the acyl-CoA/free CoA ratio 
in the mitochondria since propionyl-esters under the conditions employed are mainly produced 
inside the mitochondrion. To further investigate whether carnitine alters MCFA oxidation in 
vivo, we infused pigs (n=34) continuously with MCFA via umbilical arterial catheters; and after 
an adaptation period, carnitine was added to the infusate. The addition of carnitine increased 
MCFA oxidation (p<.01) when MCFA oxidation provided more than 20% of the metabolic 
energy (increase = 0.16 [fatty acid oxidation rate -18], r=0.74, p<.01). In addition, in 18 of 
these pigs, dicarboxylic acid (OCA, analyzed using HPLC) excretion in urine (collected via a 
bladder catheter inserted via the umbilicus) was measured over time. Carnitine supplementation 
decreased DCA excretion by 45% (p<0.05) in urine. This suggests that carnitine lowered the 
intracellular fatty acid concentration in the liver (possibly due to an increased fatty acid 
oxidation) since DCA production is correlated with the fatty acid concentration. Carnitine 
supplementation also increased plasma and liver carnitine and acetyl-carnitine concentrations and 
urinary acetyl-carnitine excretion. However, no increase was observed in muscle acetyl-carnitine. 
The increase in liver acetyl-carnitine due to carnitine and fatty acid infusion concurs with the 
hypothesis that carnitine acts as a buffer to the hepatic intramitochondrial acyl-CoA/CoA ratio, 
aiding in the export of excess acyl groups and thereby, relieving the mitochondrion of a toxic 
substance which is capable of inhibiting oxidative processes as well as the urea cycle. 
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Introduction 
Piglet mortality is a major problem for the swine industry. Mortality varies considerably across 
different production units from as low as 5 % on well-managed farms to as high as 25 % on others. 
High mortality is associated with a significant increase in costs: a larger sow herd is required 
to produce similar numbers of animals. In the last decade, efforts to improve sow herd productivity 
have focused on increasing the number of pigs born per litter, but little effort has been made towards 
decreasing mortality. Several reasons (see Fig. 1) exist for the high mortality. The underlying 
cause is, however, often associated with a lack of adequate nutrition. 
Fig. 1. Causes of mortality of piglets 
between birth and weaning in an exper-
imental swine farm (Rosmalen 1991). 
Starvation is directly caused by a lack 
of sufficient nutrition, but also trauma 
(weaker pigs are more susceptible) and 
diarrhea (lack of immunoglobulins) have 
a major nutritional component. 
Modern housing systems are designed for optimal hygiene, climate, and ease of use without 
compromising the performance of the animal. The housing of the sow with her newborn piglets, 
however, presents a dilemma. The sow needs a fairly cool environment (15 °C, Noblet et al. 1990), 
while the newborn pigs require a warm environment (35°C, Curtis et al. 1970). Achieving these 
two environments within one building is extremely costly, and often not practical. Therefore, 
the environment for the newborn pig is compromised. Newborn pigs are often housed in an 
environment which is below thermoneutrality (optimum temperature for the animal). 
Before and at birth, the pigs' metabolic rate (heat production) is equivalent to the metabolic 
rate of the sow (per unit of body weight, Gentz et al. 1970). After birth, the pig's heat loss increases 
due to evaporating birth fluids and due to the lack of a thermoneutral environment (Fig. 2). Therefore, 
the pig looses heat at a rate higher than it produces heat (which actually drops after birth), resulting 
in a drop in body temperature. The drop in body temperature initiates a fatalistic cycle of a lack 
of competitiveness (an unresponsive, weak pig), lack of milk intake, and ultimately mortality 
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Pig. 2. Heat loss, heat pro-
duction, and body temperature 
of a suckling (solid line) and 
a fasting (dashed line) new-
born pig housed at 32°C (fic-
tional data modelled after 
Noblet & Le Dividich 1981). 
Immediately after birth, the 
pigs' heat loss is much higher 
than his heat production, 
which results in a drop in 
body temperature. Only a 
healthy, suckling pig is able 
to compensate for this drop in 
body temperature. The non-
suckling pig is unable to 
control his body temperature 
and will become severely hypo-
thermic and eventually die. 
For the pig to increase his heat production, energy is required. However, pigs are born with 
limited energy reserves. Only 1 to 2% of their body weight is fat, from which about 50% can 
be used as an energy source. Glycogen is available in liver and in muscle (approximately 14.7 
g for a pig of 1.2 kg, dependent on the nutritional status of the sow), which supplies the piglet 
with energy to adequately maintain body functions for approximately 17 h (at 27°C). Together, 
fat and glycogen provide sufficient energy to remain vivid for approximately 28 h. In small 
pigs, stores are significantly less, and without food, they can remain vivid for only 8 h (Mellor 
& Cockburn 1986). Often these energy supplies, especially in a smaller pig (see Fig. 3), are not 
enough to enable the pig to cope with suboptimal circumstances after birth; and immediate milk 
consumption is necessary for the pig to survive. Colostrum, if consumed, supplies new energy, 
activates the intestinal tract, and increases metabolic rate (Gentz et al. 1970). 
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Fig. 3 . Effect of p ig le t b i r t h 
weight on mor ta l i ty within the 
f i r s t 4 weeks of l i f e ( to ta l 
mor ta l i ty a t the farm studies 
was 8.2%; van der Aar 1985). 
The hatched bars indicate the 
weight c lass of pigs which 
have good odds surviving in a 
well-managed environment, but 
often die in a poorly-managed 
environment. 
If the pig is not able to suckle, then nutritional supplementation can provide the energy needed 
and can stimulate the metabolism of the pig. The advantage of a nutritional supplement compared 
to other methods for decreasing mortality is that it can be used in existing buildings without major 
investments and can be directed specifically to animals that need the treatment. A small disadvantage 
is the need for extra labor which can be reduced by combining the labor associated with supplying 
extra nutrition with other chores, like iron supplementation and teeth clipping. 
Colostrum provides excellent nutrition for the pig, but it is not suited for use as a nutritional 
supplement for weaker pigs. The volume required to supply sufficient energy (e.g. 50% of the 
metabolic need for 1 day) exceeds the capacity of the pig's stomach. Second, colostrum is also 
a good growth medium for bacteria; therefore, it has to be prepared fresh prior to use from an 
artificial formula or from freeze-dried colostrum, or obtained manually from the sow, increasing 
the need for labor. 
Development of a nutritional supplement 
Research in our lab focusses on developing an energy supplement which provides the pig with 
a significant energy dose without suppressing the milk/colostrum consumption. Medium-chain 
triglycerides (MCT, which are fats with 6-12 carbon atoms: C6-C12) have been used successfully 
in pediatric nutrition for both premature and term babies in hospital settings and also in commercial 
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infant formulas as an energy supplement because of their unique metabolic characteristics. In humans, 
MCT have been found to spare protein, which enhances recovery of trauma patients and growth 
in premature infants (Bach & Babayan 1982, see also Chapter 3). We, therefore, focus on the 
use of medium-chain triglycerides as an energy supplement for pigs. 
Medium-chain triglycerides are derived from coconut and other tropical oils, and are commercially 
available. MCT have some advantageous characteristics which make them interesting for consideration 
as a nutritional supplement (Bach & Babayan 1982): 
* absorption and digestion is greatly enhanced compared to the long-chain triglycerides naturally 
found in sow's milk (absorbed as fast as glucose) 
* can be absorbed without being broken down in the intestinal tract; therefore, they can be 
absorbed by nonfunctioning intestines 
* can not be reesterified (stored) to a great extent; consequently, MCT have to be metabolized 
and will yield energy to the pig upon administration 
* have a high energy density (2 * the density of lactose or glucose, 7 * the density of colostrum) 
* can be stored at room temperature in a non-sterile environment 
* do not suppress colostrum consumption (Benevenga et al. 1989) 
Several studies have been published which look at survival rates of pigs after supplementation 
with MCT, but in general, no significant improvements were observed (Steinman 1986, Lepine 
et al. 1989). These experiments were executed at farms with already low mortality rates (as low 
as 5%), and the doses of MCT given were far beyond what the pig can handle physiologically 
and pharmacologically, which might have caused gastric distress and possibly led to intoxication 
(see Chapter 1). This makes interpretation of results to determine if MCT should be used at 
commercial farms for decreasing mortality difficult. It, however, indicates that our current level 
of knowledge is insufficient to recommend the use of MCT for commercial application in the 
swine industry. 
Carnitine 
Birth creates major changes in environment and nutrition, and thus, in the functioning of animals 
and humans. The fetal pig is supplied with nutrients by an intravenous infusion of a near optimum 
nutrient solution with carbohydrates as the major energy source. The neonatal pig is dependent 
on intake and digestion of milk with fat as the main energy source (up to 70%). 
Dietary fatty acids as well as fatty acids derived from lipolysis are presented to cells in the 
form of lipoproteins. Lipoproteins, however, can not enter the cells; fatty acids are released from 
triglycerides and cholesterol-esters which are imbedded in their surface by the action of lipoprotein 
lipases. The resulting free fatty acids are either taken up by the cell directly (via passive diffusion) 
or bind to albumin, which can transport the fatty acids to other tissues (Carey et al. 1983). 
Inside the cell, fatty acids can bind to fatty acid-binding proteins, which probably channel 
the fatty acids to the mitochondria and peroxisomes. In several organelles, fatty acids can be activated 
to their respective acyl-CoA esters by acyl-CoA synthetases. The product is an activated fatty 
acid, which can be utilized for oxidation (or chain-elongation). However, activation by CoA changes 
the properties of the fatty acids, eliminating their capability to passively diffuse through the inner 
mitochondrial membrane (Bremer 1983). 
To get these acyl-CoA esters inside the mitochondrion, the cell uses carnitine (B-hydroxy-y-
trimethylammonium butyrate, Broquist & Borum 1982). Via the action of carnitine acyl-transferase 
(see Fig. 4), the CoA group on the fatty acid is replaced by carnitine, creating an acyl-carnitine 
ester for which a specific carrier protein is present in mitochondria: carnitine translocate. Inside 
the mitochondrion, carnitine is replaced again by CoA recreating the active fatty acid which can 







Acyl-CoA CPT H CoA 
Mitochondrial matrix 
Fig. 4. Schematic representa-
tion of the transport of acyl-
groups over the inner mito-
chondrial membrane (Pande et 
al. 1990, CPT is carnitine 
palmitoyl transferase). 
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Carnitine translocase is a poorly understood carrier mechanism. It promotes a 1-to-l exchange 
of acyl-carnitine and carnitine; but it also allows a slow, unidirectional transport of carnitine (Bremer 
1983). 
Several forms exist for the carnitine acyltransferase enzyme which are present in different 
organelles, suggesting different roles in each organelle. The different forms of the carnitine acyl-trans-
ferase are based on chain-length specificity of the enzyme. In the mitochondria, two forms are 
present: carnitine acetyl-transferase (monomer) with a chain-length optimum for C2-C3 and carnitine 
palmitoyltransferase (tetramer) with a chain-length optimum for C10-C16 (Bremer 1990). The 
carnitine palmitoyltransferase is present in a form which can be inhibited by malonyl-CoA (present 
in the outer mitochondrial membrane) and in a malonyl-CoA insensitive form (present inside the 
mitochondrial matrix; both are distinctive proteins, Murthy& Pande 1990). The acetyl-and palmitoyl-
transferase are involved in the transport of acyl-groups in and out of the mitochondrion. In 
peroxisomes, in addition to carnitine acetyl-transferase, a third form is recognized, carnitine octanoyl-
transferase (monomer, which is often called carnitine palmitoyltransferase due to the similar chain-
length specificity) with an optimum activity towards C6-C10. The role of this acyl-transferase 
is most likely the export of products from peroxisomal fi-oxidation (see Appendix A). Recently, 
a new form has been recognized in endoplasmic reticulum, but data on its function and chain-length 
specificity are lacking (Bremer 1990). 
Less well-studied roles of carnitine involving similar transport mechanisms are the following: 
* Carnitine can aid in the transport of acetyl groups out of the mitochondria to make them 
available for fatty acid synthesis. The mechanism of this transport is a reversal of the 
mechanism for fatty acid transport into the mitochondria (Pearson & Tubbs 1967). 
* Carnitine can protect the cell against accumulation of acyl-CoA compounds of either endo-
or exogenous origin by trapping such acyl-groups as carnitine esters (no experimental data 
has been presented to proof this point). The carnitine esters formed may then be transported 
to the liver for catabolism or to the kidney for excretion in the urine (Stumpf et al. 1985). 
(Carnitine acetyl-transferase acts most likely in this fashion, since it is only present in 
the mitochondrial matrix.) Acyl-carnitines can also be broken down to free carnitine and 
a fatty acid by the action of acyl-carnitine hydrolase, an enzyme situated in the endoplasmic 
reticulum with a chain-length optimum of CIO and an activity range from C6 to C22 fatty 
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acids. The function of this enzyme is most likely to prevent accumulation of excess long-chain 
acyl-carnitines and thus acyl-CoA (Bremer 1983). 
* Carnitine esters can form a rapidly available energy supply, which has been shown to be 
true in e.g. spermatozoa, which have extremely high levels of acetyl-carnitine (Bremer 
1990). 
* Carnitine might play a role in the synthesis of CoA from pantothenic acid. The rate-limiting 
enzyme pantothenate kinase is strongly inhibited by CoA and acyl-CoA. This inhibition 
can be reversed by carnitine (not by acyl-carnitines, Thurston & Hauhart 1992). 
The need for carnitine in higher animals has to be satisfied by intake of carnitine (precursors) 
with food (carnitine is actively absorbed from the intestinal tract) or by de novo synthesis. In 
general, carnitine and its precursors are low in feedstuffs of plant origin and high in feedstuffs 
of animal origin (Robles-Valdes et al. 1976). 
The synthesis of carnitine is dependent upon the availability of trimethyllysine. Trimethyllysine 
can be derived from hydrolysis of certain (select) proteins containing trimethyllysine in a peptide 
linkage. This trimethyllysine is formed via methylation of lysine, which is one of the posttranslational 
modification reactions that protect polypeptides from degradation (Bremer 1983). Fasting increases 
carnitine levels because it promotes the breakdown of body protein which contains trimethyllysine 
(Robles-Valdes et al. 1976). 
All tissues are able to convert trimethyllysine to 7-butyrobetaine (see Fig. 5), but only the 
liver and testes (and in some species the kidney and/or brain) are able to convert 7-butyrobetaine 
to carnitine (Rebouche & Engel 1980). The concentration of carnitine in these tissues is rather 
low (400-500 [iM in infants, Shenai et al. 1984). However, other tissues such as muscle have 
very high concentrations of carnitine (3600 pM, Sped etal. 1992). Siliprandi etal. (1990) suggest 
that in those tissues an active transport mechanism exists (carnitine/7-butyrobetaine antiport). 
This "antiport" is a one-to-one exchange port between carnitine and 7-butyrobetaine, thought to 
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Fig. 5. The pathway of carni-
tine biosynthesis (Broquist & 
Borum 1982) . From left to 
right are: names of enzymes, 
compounds formed, factors 
involved, and structures of 
compounds formed (g=gamma). 
Mammals are unable to catabolize carnitine; however, micro-organism in the intestines are 
able to convert carnitine to trimethylamine (main end product), trimethylamine-oxide, butyrobetaine 
and crotonobetaine. The extent of this pathway is not known but is generally considered minor. 
A mammalian system for carnitine degradation has been reported which involves the enzyme carnitine 
decarboxylase. The data on this enzyme are, however, contradictory, and possibly confounded 
by microbial action on carnitine (Bremer 1983). 
Carnitine in the fetal and the newborn pig 
Carnitine concentrations in the fetal pig decline in plasma after the 90th day of gestation (from 
32 pM to 7 JUM). The concentration in muscle (which is the main storage site for carnitine) increases 
from day 60 to parturition (from 1.4 pmol/g non-collagen protein to 7.5 pmol/g non-collagen 
protein, Baltzell et al. 1987, Gross & Henderson 1984). 
At birth, the plasma carnitine concentration is low (6-8 pM) and is considered limiting for 
the oxidation of palmitic acid and thus for the energy supply of the neonatal pig (Garber & Froseth 
1984). Other factors which might limit 8-oxidation are the low number of mitochondria (Bischoff 
etal. 1969) and a lower capacity of the mitochondria for B-oxidation (approximately 50%, Bieber 
etal. 1973). Although carnitine levels are lowatbirth, the newborn infant excretes carnitine before 
the onset of feeding, mainly as acetyl-carnitine (Novak et al. 1979). 
Colostrum contains large amounts of carnitine (-esters), mainly acetyl-and isovaleryl-carnitine 
(total carnitine content is 440 nmol/ml, acetyl-carnitine and isovaryl-carnitine make up 45 % each), 
providing the piglet with ample carnitine to resupply his tissue stores. Within 2 days after parturition, 
the level of carnitine in the milk decreases considerably (Kerner et al. 1984). Carnitine levels 
exceeding the kidney threshold (50-60 /iM, Engel etal. 1981) result in the excretion of (preferably 
acyl-)carnitine by the kidney (Gross & Henderson 1984, Olson & Rebouche 1989). Novak et al. 
(1979) suggested that the majority of the excreted carnitine is in the form of acetate esters. Only 
in adults does the urine contain significant amounts of free carnitine. 
The concentrations of carnitine in the pig (Kerner etal. 1984) are different from the concentrations 
in the rat as determined by Robles-Valdes et al. (1976). For example, pig liver was low in carnitine 
at day 0 (95 pM) increasing to day 2 (296 pM); while in the rat liver, the concentration declined 
from day 1 to day 3 from 570 to 400 pM, which was still higher than in the piglet. This raises 
questions such as whether the rat has a higher need for carnitine, of if the 8-oxidation is more 
important in neonatal rats. 
Research focus: the role of carnitine in MCFA oxidation in vivo 
" The critical need for carnitine coupledwith reduced stores of carnitine and reduced 
biosynthesis capability in the neonate compared with the adult have caused nutritionist 
to consider the possibility that carnitine may be an essential nutrient for the human 
neonate" (Baltzell et al. 1987). 
The apparent carnitine deficit found in newborn pigs may limit their capacity to oxidize fatty 
acids during the first days of life because the fatty acids can not be transported into the site of 
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oxidation. Therefore, they may not be able to optimally contribute to the energy supply of the 
pig. Indeed, experiments have shown that addition of carnitine can enhance oxidation of long-chain 
fatty acids in newborn pig-liver cells (Wolfe et al. 1978). 
Medium-chain triglycerides, after breakdown to medium-chain fatty acids (MCFA), do not 
require carnitine for their oxidation. In contrast to long-chain fatty acids, MCFA can enter liver 
mitochondria by passive diffusion where they can be activated (Groot & Hulsmann 1973, see 
Chapter 4). Although the dogma states that MCFA can be oxidized in the absence of carnitine, 
two research groups have suggested recently that carnitine still plays a role in the oxidation of 
MCFA (Rebouche et al. 1990, Rossle et al. 1990). The data presented by these two groups is, 
however, not conclusive; and it has not been determined whether carnitine supplementation to 
a carnitine deficient subject can improve the utilization of MCT. This possible involvement of 
carnitine in medium-chain fatty acid metabolism has become the focus of this thesis. 
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Chapter 1. Toxicity of medium-chain fatty acids and triglycerides 
1.1 Introduction 
In addition to the beneficial effects of MCT as mentioned in the introduction, MCT have been 
found to be toxic. This toxicity has clinical implications since several disease have been identified 
in which endogenously produced fatty acids accumulate whose concentration are a determining 
factor in the outcome of the disease. Shaw (1985) determined that when plasma free fatty acid 
concentrations exceeded .85 mM the chance of surviving became less than 35%, while when plasma 
free fatty acid level remained less than .85 mM the chance of surviving was greater than 70% 
in children affected by Reye syndrome. 
Toxic concentrations of MCFA can be reached in the pig with oral MCT doses which are 
at a level considered practical as an energy supplement. Several experiments in our lab have illustrated 
this. For example, in a preliminary trial for the experiments as described in Chapter 4, three (out 
of four) pigs died; and the fourth pig seemed to be in an unresponsive coma. Since the infusion 
rates used were higher than the infusion rates in other trials, combined with the symptoms seen, 
we had to conclude in retrospect that these deaths were most likely caused by MCFA intoxication. 
The oral feeding studies as performed by T.M. Wieland and Xi Lin confirmed this notion when 
emulsifying MCT led to intestinal uptake rates resulting in plasma levels which caused lethargy 
and coma, and in some cases death. 
The mechanism for this toxicity has not yet been determined, but it might explain in part why 
researchers were unable to see beneficial effects of MCT on survival in piglets. In this chapter, 
several mechanisms through which medium-chain fatty acids may be toxic will be discussed along 
with the possible role carnitine has in this toxicity. 
1.2 Accumulation of fatty acids 
Fatty acids (NEFA, FFA) are normally present in the body and are utilized as a fuel and as 
a structural component, mainly of biological membranes. In a healthy subject, the concentration 
of fatty acids is determined by dietary uptake, lipogenesis, and lipolysis, increasing fatty acid 
levels, and by reesterification and oxidation decreasing fatty acid levels. Lipolysis, reesterification, 
and oxidation are regulated to maintain a non-toxic fatty acid level (Murray et al.1988). Several 
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diseases, however, can lead to an accumulation of fatty acids resulting in a high, possibly toxic 
level of fatty acids. Two of these diseases are Reye syndrome and MCAD deficiency (Medium-chain 
Acyl-CoA Dehydrogenase deficiency). 
Infants appear to be especially susceptible to these diseases (Roe & Coates 1989). Several 
reasons might explain this, but none are accepted in the literature. One possibility is that the carnitine 
biosynthesis of infants in hampered. Carnitine can be synthesized de novo; but it is questionable 
whether newborns and infants can synthesize carnitine at a rate sufficient to compensate for growth, 
urinary losses, and low body stores if intake (via animal products) is low (Sachan, personal 
communication). The carnitine stores are even lower when 8-oxidation is hampered; toxic acyl 
compounds can be excreted in urine as carnitine esters, relieving toxicity from the system, but 
causing carnitine deficiency (Roe & Coates 1989, Hamosh et al. 1991). 
Fig. l . i . Free f a t t y acids 
concentrat ion in children and 
young adul t s (average per age 
group). Plasma samples were 
obtained from 600 students of 
varying age and free f a t ty 
acid leve ls were determined 
(Rogiers 1981). 
6 8 10 12 14 16 18 20 22 
Age (y) 
A second reason might be the elevated plasma fatty acid levels of infants. This is poorly illustrated 
in literature; but data from Rogiers (1981, Fig. 1.1), which does not include the age category 
at risk, suggests that children indeed have higher levels of free fatty acids than adults (she mentioned 
that infants had even higher levels of free fatty acids). If it is valid to extrapolate this graph to 
the age group at risk (6 to 24 months), then this data might explain some of the increased suscepti-
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bility of infants for fatty acid toxicity. High levels of fatty acids leave a smaller margin between 
actual levels of fatty acids and toxic levels of fatty acids; in other words, a small derailment of 
8-oxidation causes fatty acids to accumulate to toxic levels. 
A third factor may be the metabolic rate of a small subject versus a tall subject, e.g. a child 
versus an adult. The metabolic rate of a child will be higher per kg of body weight than the metabolic 
rate of an adult; therefore, the amount of fuel needed to supply the body with energy will be higher 
for the child per kg of body weight (van Es et al.1983). This means that infants, in which the 
(greater) flux of fuel to energy becomes interrupted/blocked, this fuel can reach to a toxic concentra-
tion in a much shorter time than an adult can since toxicity is most likely related to a concentration 
of fatty acids. 
A fourth (speculative) factor might be the distribution of energy in infants versus adults. Due 
to hormonal profiles, infants are predispositioned to grow/spare protein (gluconeogenic substrate), 
while adults are much more prone to use protein for their energy supply (Verstegen, personal 
communication). This means that in a negative energy balance infants will rely more on lipids 
than adults will (lipids contribute a larger proportion to the total energy supply). Therefore, the 
flux of lipids in infants is higher, which in the case of a blockage of 8-oxidation will lead to a 
more rapid accumulation. 
1.3 MCAD deficiency 
Medium-chain acyl-CoA dehydrogenase deficiency is a recently discovered disease (Gregersen 
et al. 1977, Stanley et al. 1983) and is caused (most commonly) by an autosomal recessive inherited 
disorder which leads to the inability to produce sufficient active medium-chain acyl-CoA dehydroge-
nase, one of the enzymes of the mitochondrial 8-oxidation cycle. The symptoms observed in MCAD 
deficiency are similar to those observed in SIDS (Sudden Infant Death Syndrome) which explains 
the late discovery of MCAD deficiency. MCAD deficiency is highly lethal; the mortality rate 
is 59% during the first episode (at less than 2 years of age, Rinaldo et al. 1989). 
MCAD patients are still frequently miss-diagnosed with SIDS (Rinaldo et al. 1989), which 
is a major cause of infant mortality (1/s of infant mortality in Belgium, Rebuffat et al. 1991). 
Postmortem analysis is usually not performed (often the child dies at home, and when it arrives 
in the hospital, it is in an advanced stage of rigor mortis; and there is "no need for such an analysis 
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since it is SIDS"). Several studies, however, have been performed to determine the real cause 
of death in SIDS cases; and MCAD deficiency is probably the main genetic defect leading to SIDS 
(Rinaldo etal. 1989, Harpeyetal. 1990). Estimates for the total contribution of MCAD deficiency 
to SIDS mortality range from 5 to 10 percent (Roe & Coates 1989, Harpey et al. 1990). These 
estimates are based on a subgroup of SIDS patients with fatty infiltration in liver since it is assumed 
that only these infants suffered from a lipid oxidation disorder. It is questionable whether there 
is a causal link between MCAD deficiency and lipid infiltration of the liver since non-fasting fatty 
acid oxidation in minimally affected in MCAD deficiency. If this link is not present, then these 
figures could underestimate the occurrence of MCAD deficiency. 
Methods for diagnosing MCAD deficiency include urinary acyl-carnitine and acylglycine-conjugate 
profiles. A carnitine loading assay can be performed to stimulate accumulation of medium-chain 
carnitine esters in urine. The carnitine profile of an MCAD deficient patient will show accumulation 
of medium-chain carnitine esters, with approximately 60% of the carnitine present as octanoyl-
carnitine (Roe et al. 1985, Roe et al. 1986, Rinaldo et al. 1989). Acyl-glycines (suberyl- and 
hexanoyl-glycine) can be formed inside the mitochondria of a subject affected by MCAD deficiency 
(involves glycine-N-acylase system, Treem et al. 1986). Other diagnostic methods which impose 
an unacceptable high risk on the patient are prolonged fasting (Gregersen et al. 1977) and the 
use of a ketogenic diet (Divry et al. 1983). Both stimulate 8-oxidation to induce symptoms of 
MCAD deficiency (prolonged fasting does not always trigger MCAD deficiency symptoms). 
The most explicit diagnostic tool is the determination of MCAD activity in, for example, cultured 
fibroblasts or from liver cells (more invasive). Table 1.1 (Duran et al. 1986) shows results from 
a family in which B (an infant) died from MCAD deficiency. Other family members were submitted 
to a 17 h fast, and a fibroblast sample was taken. A and K (children) and the father appear to 
have lowered octanoate (C8) oxidation capacity. This table clearly shows that oxidation of medium-
chain fatty acids is decreased in affected subjects compared to controls. 
Subjective observations which can be made in MCAD deficient patients are a sweaty foot odor 
or acrid, fatty smell on breath or skin (Harpey et al.1987). 
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Table 1.1. In vitro oxidation of octanoate (C8) to C02 (nmol C02/10s cells/h) in 
a family in which B died of MCAD deficiency. Fibroblast samples were obtained after 
a 17 h fast from family members of B and from controls (2-4 years of age, after 
a 24 h fast) . B underwent a postmortem liverbiopsy. Succinate and butyryl-CoA (C4-




























A typical case of MCAD deficiency can be described as follows. The infant will refuse to 
eat, often due to symptoms associated with a viral infection or immunizations (Harpey etal. 1990). 
After 24-40 h of fasting (vomiting and/or diarrhea will decrease this time period since this empties 
the gastrointestinal tract, leading to a decreased energy influx from the gut), the infant will fall 
into a "deep sleep" (unresponsive, low muscle tone) followed by coma, cerebral edema, cardiac 
failure, and/or respiratory arrest (Duran et al. 1986). A postmortem analysis will often reveal 
a cerebral edema and lipid infiltration of the liver (Roe et al.1985). Affected plasma parameters 
are glucose (hypoglycemia, due to the lack of fuel some tissue will keep using glucose, Bartlett 
et al. 1991, Treem etal. 1986), ammonia (hyperammonemia, high levels of fatty acids will inhibit 
the urea cycle, Trauner et al. 1988, Treem et al. 1986), ketone bodies (hypoketonemia, since 
no excess acetyl-CoA is available, Bartlett etal. 1991) and, of course, increased levels of fatty 
acids (see table 1.2, Duran et al. 1986, Stanley et al. 1983). 
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Table 1.2. Free f a t t y acid and ketone body concentrat ions (/miol/1) of a family 
in which B was hosp i ta l i zed for MCAD deficiency (same family as in tab le 1.1). 
Familymembers were submitted to a 17 h f a s t . Control chi ldren (2-4 years of age) 





































The cause of MCAD deficiency is the lack of sufficient activity of the MCAD enzyme. If 
fatty acid mobilization is stimulated, then this will lead to accumulation of fatty acids via the following 
mechanism (hypothetical): fatty acids (long-chain) are released from triglycerides because of the 
stimulated action of lipases. These are stimulated first by fasting (low insulin/glucagon ratio) and 
second by the presence of a viral infection (at least present in 60% of the cases, Treem et al. 
1986). This will lead to an excess of fuel entering the cell. Inside the cell, a pool of fatty acids 
is present which can enter two routes of oxidation: peroxisomal (minor route) and mitochondrial 
oxidation. 
The peroxisomal 8-oxidation (see Appendix A) is an incomplete and modified version of the 
8-oxidation in mitochondria. To enter peroxisomes, fatty acids are supposedly activated to their 
acyl-CoA ester upon entrance into the peroxisomes. These acyl-CoA are chain-shortened, and 
acetyl-CoA is produced. The affinity of the long chain acyl-CoA dehydrogenase enzyme for the 
acyl-CoA decreases with decreasing chain length. At a chain length between C6 and C10 (mainly 
C8), the fatty acid will exit the 8-oxidation and will be exported out of the peroxisome, preferably 
as a carnitine ester (Vamecq & Draye 1989). Acetyl-CoA will either be utilized in the peroxisome 
for e.g. cholesterol synthesis, the cytosol, or will be transported into the mitochondria (if carnitine 
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is available). 
Peroxisomes, and thus peroxisomal 8-oxidation, can be stimulated by high levels of fatty acids 
(Cannon et al. 1982) and also by aspirin (Vamecq & Draye 1989, see also Reye syndrome), which 
used to be a common treatment for viral infections in infants. 
The second route of fatty acid oxidation is via the mitochondrial 8-oxidation. Long-chain fatty 
acids need to be activated (which can happen in the outer mitochondrial membrane, cytosol, and 
in peroxisomes). These acyl-CoA compounds are then converted to acyl-carnitine in the outer 
mitochondrial membrane (Pande et al. 1990); and this acyl-carnitine complex can be translocated 
into the mitochondrial matrix, where the carnitine is replaced with a CoA. The resulting acyl-CoA 
is then available for 8-oxidation (Bremer 1983 and Fig. 1.2). 
The 8-oxidation system consists of 4 enzymes from which several consists of subclasses with 
their own chain-length specificity. The following subclasses are recognized for the acyl-CoA 
dehydrogenases: long-chain acyl-CoA dehydrogenase (LCAD), with an optimum activity towards 
C14-C20, medium-chain acyl-CoA dehydrogenase (MCAD), with an optimum activity towards 
C6-C12 and short-chain acyl-CoA dehydrogenase (SCAD), with an optimum activity towards 
C4 and C6 (Harpey et al. 1990). 
If MCAD activity is lacking or low and fatty acid oxidation is stimulated (high influx of fatty 
acids into the cell), then long-chain fatty acids will undergo 8-oxidation, but medium-chain acyl-CoA 
will start accumulating in the mitochondria. These acyl-compounds are, however, bound to CoA. 
Since CoA is present inside the mitochondrion in limited quantities (which respond only slowly 
to changing circumstances such as fasting, in which intramitochondrial CoA concentration doubles), 
the accumulation of CoA in medium-chain acyl-CoA esters can deplete a large portion of the CoA, 
which will lead to a deficiency of CoA in the mitochondria. Excess amounts of acyl-CoA compared 
to free CoA will inhibited mitochondrial function, since free CoA is required for the TCA cycle 
and 8-oxidation and the ratio of free CoA to acyl-CoA greatly affects the urea cycle. The accumulation 
of acyl-CoA can, therefore, shut down mitochondrial activity. Carnitine might play a role in this 
toxicity by exporting acyl-groups from the mitochondrion into the cytosol as a carnitine esters. 
This will free up CoA but at a cost to carnitine. 
18 
Out&^oX FA Acyl-CoA Acyl-CoA 
. . N ^ 1 7 Carnitine 
AtJfSoA , T transferase..! 







Fig. 1.2. Schematic represen-
tation of the 8-oxidation in 
mitochondria. Fatty acids are 
activated to CoA esters, which 
can be translocated into the 
mitochondrion as a carnitine 
ester. In the mitochondrion, 
enzymes with different chain-
length specificity are present 
to break down the acyl-chain. 
The activity of the peroxisomal 8-oxidation is (hypothetical, no proof to support this) not hampered 
during this scheme of CoA depletion since peroxisomes have their own CoA pool and the exportation 
of end product is not carnitine dependent, but preferably carnitine conjugated (Vamecq 1989). 
This will lead to a further accumulation of acyl-carnitine in the cytosol, as well as to an accumulation 
of medium-chain fatty acids (which can explain the high levels of octanoate in plasma and octanoyl-
carnitine in urine). 
Acyl-carnitines are very water soluble and upon accumulation, they can be cleared by the kidney 
which preferably excretes acyl-carnitines (>C2-carnitine). This excretion can lead to a carnitine 
deficiency as illustrated in table 1.3, further impairing oxidation capacity (since mitochondrial 
8-oxidation of long-chain fatty acids is carnitine dependent). It also hampers the only mechanism 
the body has to relieve CoA from (toxic) acyl-CoA compounds (without oxidizing the acyl-compound, 
Coates et al. 1985). If CoA is limited, then oxidation (8-oxidation as well as the TCA cycle) will 
be severely hampered since intermediates of both pathways have to be conjugated to CoA (Stumpf 
et al. 1985, Harpey et al. 1990). Ultimately, the continuing influx of fatty acids and the lack of 
oxidation of these fatty acids will lead to accumulation of fatty acids and acyl-CoA to levels which 
might be toxic. 
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Table 1.3. Plasma carnitine status (/xmol/1) in four patients with identified MCAD 
deficiency and one patient with an expected MCAD deficiency (DCA=dicarboxylic 
aciduria). The ratio of free to acyl-carnitine, as well as absolute levels, are 






















1.4 Reye syndrome 
Reye syndrome is, just as MCAD deficiency, often confused with SIDS, suggesting that symptoms 
(and mechanisms) are similar. Reye syndrome is fairly lethal: 40% of the infants/children affected 
die (Ansevin 1980). Reye syndrome is characterized by liver damage, swollen mitochondria and 
fragmented cristae. Differences in symptoms with MCAD deficiency are that no acyl-glycine 
conjugates are found in urine (since acyl compounds do not accumulate inside but rather outside 
the mitochondria?) and that the urine will contain significant amounts of acetyl-carnitine (and 
relatively low amounts of octanoyl-carnitine). Also ketogenesis is less inhibited (Treem et al. 
1986). 
The difference between MCAD deficiency and Reye syndrome is the underlying cause. In 
MCAD deficiency an enzyme deficiency causes accumulation of fatty acids; in Reye syndrome, 
the mechanism is not clear (Pranzatelli & De Vivo 1987). 
Two prime factors are almost always identified in Reye syndrome: a viral infection and the 
use of medication to cure this, like aspirin (USA) and phrotozombin (Europe, treatment of 
nasopharyngitis, Shaw 1985). 
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Table 1.4. Effect of viral infections and aspirin on the oxidation rate of palmitate 
(jrniol C02/g protein/h). Mice were infected with an influenza virus and/or fed 
salicylic acid, with or without carnitine (100 mg/kg BW of D,L-carnitine) . 36 h 
post infection/feeding initiation, mitochondrial palmitate oxidation capacity was 







































The mechanism causing toxicity is suggested by Trauner (1988) to be the destructive effect 
of both aspirin and virus on the structural integrity of the mitochondrial matrix. This is, however, 
easily refuted from Trauners' own data (see table 1.4). Trauner infected mice with an influenza 
virus and/or fed them aspirin. After 36 h, mice were killed; and mitochondria were isolated to 
measure the oxidation rate of radiolabeled palmitate in vitro. The viral infection and aspirin both 
had negative effects on the oxidation capacity and on structural integrity of the mitochondria. 
The addition of carnitine, however, completely prevented any damage to the mitochondria; and 
the oxidation rate of palmitate in carnitine fed animals was not decreased. No mechanism is known 
to exist which suggests that carnitine has an effect on the ability of a virus to infect a cell. Although 
some treatments are missing (e.g. carnitine plus aspirin with and without virus) and not all treatments 
are consistent (virus dose in the aspirin fed animals was lower than in the animals which received 
only virus), these data (table 1.4) suggest that the presence of the virus and/or salicylic acid caused 
a secondary carnitine deficiency. Other researchers were not able to identify a serum factor responsible 
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for the mitochondrial damage other than fatty acids (Pranzatelli & De Vivo 1987). 
Several factors may contribute to Reye syndrome. Aspirin is a peroxisomal proliferator (Vamecq 
& Draye 1989), increasing peroxisomal 8-oxidation capacity (Corkey et al. (1988) showed higher 
numbers of peroxisomes in affected infants). Second, aspirin has a very high binding affinity for 
the fatty acid binding sites on albumin (the main transport protein of fatty acids in plasma). A 
normal dose of aspirin (supposedly 100 mg/kg body weight) is sufficient to "cover" all fatty acid 
binding sites on albumin in an infant (Shaw 1985). This will increase the active fatty acid concentra-
tion which will stimulate peroxisomal proliferation even more (Cannon et al. 1982). The viral 
infection increases this problem by enhancing lipolysis (Pranzatelli & De Vivo 1987). Ansevin 
(1980) showed that added BSA (bovine serum albumin) could completely reverse all symptoms 
of Reye syndrome as observed on the mitochondria. A recent paper from Deschamps (1991) suggests 
a third role for aspirin. Salicylic acid can be activated in mitochondria to a CoA ester, thereby 
depleting free CoA as well as carnitine, which is in agreement with the theory that free CoA depletion 
might be the underlying reason for medium-chain fatty acid toxicity. 
I hypothesize that the excess of free fatty acids leads to an overstimulation of peroxisomal 
8-oxidation while mitochondrial oxidation "lags behind". The mitochondria are not able to handle 
the large amount of peroxisomal products (possibly due to salicilyl-CoA intoxication or a "sub-clinical 
8-oxidation disorder") which will lead to an accumulation of acyl-CoA and carnitine intermediates 
(acetyl- and octanoyl-carnitine, mainly acetyl-carnitine: Corkey et al. 1988) in the cytosol. These 
carnitine esters are excreted into the plasma and cleared by the kidney, which will lead to a secondary 
carnitine deficiency (carnitine deficiency is shown by Treem et al. 1986, Stumpf et al. 1985, data 
similar to data presented in Table 1.3), which in a catabolic state (relying primarily on fatty acids 
for fuel), can become detrimental very rapidly. Carnitine stores in the body are limited and can 
be depleted in a short time (Stumpf et al. 1985). Peroxisomal oxidation is probably less affected 
by the carnitine deficiency, leading to accumulation of significant amounts of acetyl- and medium-
chain acyl-intermediates (extrapolated from Rabinowitz et al. 1978). 
Both liver and especially brain are low in carnitine (compared with other tissues and plasma) 
(Borum, personal communications), and both brain and liver are identified as the tissues with 
most extensive mitochondrial damage. Whether a causal relationship exists has not been investigated. 
Mitochondria are damaged by the high levels of fatty acids, maybe since the fuel transport 
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in the cells is channelled towards the mitochondria which causes a higher "active concentration" 
of fatty acids around the mitochondria (or maybe due to the different composition of the mitochondrial 
membrane). Other organelles will be damaged if severity increases, which will lead to cell necrosis 
(and e.g. destruction of myelin sheets, Pranzatelli & De Vivo 1987). 
1.5 Dietary intake leading to toxicity 
A second mechanism by which fatty acids can reach toxic levels is by dietary intake. The only 
group of fatty acids which have been shown to lead to such massive absorbtion rates from the 
gastro-intestinal tract are the water-soluble medium-chain fatty acid (see introduction). The uptake 
of MCT (Medium-Chain Triglycerides) from the GI tract is more efficient than the uptake of LCT 
(Long-Chain Triglycerides) due to enhanced digestion and absorption of the MCT (with the maximum 
efficiency for tricaproin, tri-C6). Lipases have the highest affinity for MCT and will digest MCT 
preferably and also at higher rates. MCFA (medium-chain fatty acids) can be taken up through 
the gastric mucosa, leading to an increased absorption area (Hamosh et al. 1991). 
After uptake, MCFA can be transported directly (as MCFA or MCT) via the portal vein to 
the liver. This leads to a much greater influx from the gastro-intestinal tract, leading to a much 
faster accumulation of fatty acids in the cell (Hamosh et al. 1991). 
MCFA are not reesterified in the liver and are not stored in adipose tissue to a great extent. 
This makes them obligatory fuels and when influx exceeds oxidation capacity, this will lead to 
accumulation. 
MCFA oxidation is not regulated in the cell by the activity of carnitine palmitoyl transferase 
(major regulator of long-chain fatty acid oxidation via binding of malonyl-CoA, Bieber 1988), 
since MCFA can diffuse freely through the mitochondrial inner membrane. To what extent carnitine 
is involved in the oxidation of MCFA is a point of discussion. Activation of fatty acids in the 
muscle occurs in the cytosol, and activated MCFA can not enter the mitochondria without being 
converted to acyl-carnitines (Aas 1971). In liver, some of the MCFA will be activated before 
entering the matrix, and these acyl-CoA are dependent upon carnitine for their oxidation (Bieber 
1988). 
Questionable is if MCFA feeding can lead to carnitine deficiency, which will impair oxidation 
of long-chain fatty acids. The carnitine deficiency is, however, not essential for the toxicity, but 
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is a mechanism by which fatty acid oxidation can be impaired, leading to levels which are toxic. 
In MCT feeding trails using pigs, levels of up to 15 mM in plasma were measured (which 
did not represent a steady state! Odle et al., unpublished data), and according to research from 
Dahl (1968) and Zieve et al. (1974) these levels exceed toxic levels. Indeed, animals died during 
these feeding trials. 
1.6 Possible mechanisms for the toxic action of fatty acids 
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Weber (1966) determined the effect of high levels of fatty acids (C8, octanoate) on the activity 
of enzymes of the glycolysis and found that all unidirectional enzymes (not involved in gluconeo-
genesis) were inhibited up to 100% by high levels of fatty acids leading to a decreased flux of 
pyruvate into the TCA cycle. The effect of this inhibition in the case of an MCAD deficient patient 
is a further decrease in energy production and an impairment of the oxidation of acetyl-CoA. 
Inhibition of glycolysis is not a causal factor in fatty acid toxicity as presented in this paper, since 
inhibition of the glycolysis would lead to an impairment of the TCA cycle, which would lead 
to excessive production of ketone bodies. 
The inhibition of enzymes shown by Weber might be attributable to acyl-CoA, but his work 
does not determine the causal factor. Acyl-CoA compounds are accepted as being toxic and can 
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inhibit several essential enzymes, for example the two enzymes of the urea cycle present in the 
mitochondria: ornithine transcarbamoylase and carbamoyl synthetase (Trauner et al. 1988). 
w-oxidation is an alternative pathway of fatty acid oxidation which becomes active if fatty 
acid levels increase. Enzymes involved are cytochrome P450 (endoplasmic reticulum), alcohol dehydro-
genase and aldehyde dehydrogenase (cytosol). The activity of this pathway is directly correlated 
to the concentration of fatty acids. The function of this pathway is unclear, and hypothesized is 
that it might either detoxify high levels of fatty acids (which is unlikely since its products are 
toxic) or that it might be a mean of converting fatty acids to TCA cycle intermediates (succinate, 
Mortensen 1980, Draye & Vamecq 1989). The second function is more likely, and fits better 
with existing evidence. 
Table 1.5. Urinary dicarboxylic excretion (mmol/mol creatinine) of a MCAD patient 
(Severine) during experimental fasting and while healthy, compared to ketotic, 
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Dicarboxylic acids can undergo 8-oxidation for several cycles. In peroxisomal 8-oxidation, 
medium-chain dicarboxylic acids are formed, which will eventually be excreted into the urine 
(adipic, suberic and sebacic acid: C6, C8 and C10 dicarboxylic acid, leading to aciduria). 
Mitochondrial 8-oxidation of dicarboxylic acids might lead to formation of succinate (Vamecq 
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& Draye 1989). Dicarboxylic acids are acidic, and accumulation of these acids will lead to acidosis. 
Presence of dicarboxylic acids in the urine is an indicator for 8-oxidation disorders (see table 
1.5, Mortensen 1986). 
High levels of fatty acids or acyl-CoA as well as a decrease in the ATP/ADP ratio (Stumpf 
et al. 1985) will inhibit the urea-cycle (at the level of ornithine transcarbamoylase and carbamoyl 
synthetase) which will lead to accumulation of ammonia (Trauner et al. 1988). Ammonia is toxic 
by itself but does not cause the symptoms of fatty acid toxicity; Ansevin (1980) showed that NH3 
toxicity did not mimic the symptoms of Reye syndrome, while octanoate did. Ammonia will, 
however, interact with fatty acids in causing toxicity (see Fig. 1.4). 
Fig. 1.4. In te rac t ion of ammo-
nia and f a t t y acids in indu-
cing coma in r a t s (created 
d a t a s e t ) . Rats were injected 
with octanoate and ammonia a t 
d i f f e r en t concent ra t ions 
( I .P . ) . Upon induction of coma 
(*), blood was col lec ted and 
analyzed for f a t t y acid and 
ammonia l eve l . No coma s t a t e 
was achieved in animals marked 
O (Zieve e t a l . 1974). 
plasma FA (nm/ml) 
Fatty acids are detergents. A simple example of this is the use of SDS-PAGE to determine 
the size of a protein: the fatty acid-sulfate degenerates the protein, unfolding it to a linear strand 
and rendering the enzyme inactive. The detergent effect might also act on the cell membrane, 
leading to disruption and altered fluidity. This will lead to altered transport functions and binding 
functions of enzymes associated with the cell membrane (Shaw 1985, Schmidt & Lankisch 1978). 
The biological significance of the detergent effect in fatty acid intoxication is, however, not clear. 
The chain length of the involved fatty acid is important in this aspect. Long-chain fatty acids 
are more effective detergents, but their solubility is lower. Medium-chain fatty acids are less potent 
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et al. 1991), which might make their overall toxicity more significant. No data is available (to 
my knowledge) which quantified the detergent effect of fatty acids in vivo. 
In vivo detergent degeneration was observed during an infusion trial using CIO. Lysis of red 
blood cells was observed, which seemed to be dependent on the infusion rate of the CIO. In the 
most severe cases, "plasma" became dark red, and urine dark red to black, suggesting a severe 
lysis of red blood cells leading to hemoglobinuria. These animals died during the infusion. C8 
infusions were carried out at levels which were 2 fold higher without visible lysis of red blood 
cells, suggesting that the chain length of the fatty acid is a major factor in this detergent effect. 
Since the in vivo toxicity symptoms with CIO were very different than with C8, it appears unlikely 
that a detergent effect is the cause of mortality when C8 is infused. 
Kim et al. (1983) showed that octanoate can produce extensive ultrastructural and functional 
damage to mitochondria of the choroid plexus. This might suggest that the effects seen are mediated 
by detergent activity of fatty acids, since Trauner (1988) and others reported similar findings in 
Reye syndrome (Trauner, however, attributed the ultrastructural changes to the action of a virus). 
Another possible (hypothetical) mechanism of toxicity is overstimulation of protein kinase C (PKC). 
PKC levels are especially high in brain tissue (Sekiguchi et al. 1988) where it has a role in membrane 
conductance (Nishizuka 1989). 
The brain does not normally oxidize fatty acids, and it achieves this most likely by active 
reesterification of fatty acids upon passage through the blood-brain barrier (Pardridge 1991). This 
reesterification might, however, be the fatal link in MCFA toxicity, since the esters of glycerol 
and MCFA are watersoluble, and diglycerides of C8 are the most potent stimulators of PKC in 
vitro (Conn etal. 1985). No experiments were done in which glycerol esters of MCFA were measured 
in brains (reticular formation) of infants affected by fatty acid toxicity. 
Evidence for involvement of PKC is limited. Arguments to justify research in this area might 
be: especially tissue which is very dependent on ion-gradients are affected by fatty acid toxicity 
and carrier-mediated transport of some ions seems to be impaired by the fatty acid toxicity (Kim 
et al. 1983, transport of many factors is dependent on the Na+ gradient over the cell membrane). 
PKC overstimulation will lead to an inhibition of the Na+/K+ ATPase activity (decreases ion-gradient, 
Blackshear et al. 1988) and also stimulates (decrease of sensitivity to intracellular H+) the Na+/H+ 
exchange protein (increasing intracellular pH, Sekiguchi et al. 1988). Dahl (1968) demonstrated 
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that there was a high correlation between the concentration of fatty acids causing coma in 50% 
of the treated rats, and the concentration of fatty acids leading to a 50% inhibition of the Na+/K+ 
ATPase in vitro, using different chain-length fatty acids as a substrate (Fig. 1.5). (NH3 interferes 
with the Na+/K+ pump by substitution for K+, and will also deplete the TCA cycle from a-keto-
glutarate (Pranzatelli & De Vivo 1987), which will lead to a further impairment of the oxidation 
capacity.) Sodium-potassium-ATPase (as well as the Na+/H+ exchange protein) is involved in 
regulating the ion-balance over cell membranes and plays an important role in functioning of neural 
cells. Dahl (1968) however reported that ouabain, an inhibitor of Na+/K+ ATPase did not cause 
coma/death, suggesting that the effect of fatty acids on the Na+/K+ ATPase were correlated with 
the causal factor, but not by itself the cause of the toxic effects. 
In support of involvement of PCK is the data from McCandles (1985), who injected octanoate 
into mice at toxic levels, and looked at energy metabolism of neurons. He concluded that oxidative 
phosphorylation and mitochondria were not affected, however, the ATP concentration was lowered, 
and the electrical output of the cells was affected. Miles (1991) used EEGs to measure brain activity 
after injection of octanoate and concluded that there was a slowing and a reduction of the electric 
amplitudes. These findings suggest again that membrane potentials are affected by fatty acids 
through affecting PKC, however, changing membrane integrity might have similar effects on the 
concentration gradients of certain ions over the cell membrane, and therefore, this data does not 
prove a role for PKC. 
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200 
fatty acids which induced coma 
in 50% of the animals compared 
150 to the concentration of fatty 
C» acids required (in vitro) to 
£ inhibit the Na+/K* ATPase 
100
 % activity to 50% of the control 
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1.7 Future research directions 
Of major importance is to elucidate the mechanism of toxicity in MCAD deficiency and Reye 
syndrome, as well as in feeding of MCT. MCT are being used more and more in hospital settings 
for both parenteral and enteral nutrition (imagine the effect of feeding MCT to an MCAD deficient 
person!). Feeding and infusion trials (Chapter 3 and 4) did not use excessive doses, but levels 
meeting basal energy requirements of the animals for approximately % to VA day. MCAD-like 
symptoms resulting in mortality was the result!. 
Several other diseases, besides MCAD deficiency and Reye syndrome, in which fatty acid 
toxicity might be involved, exist, some with even a greater (estimated) incidence than MCAD 
deficiency. Understanding the underlying mechanism is a step towards finding a cure for a severely 
comatose patient arriving at intensive care, their last stop if we stay reluctant. 
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Chapter 2. Quantification of carnitine esters by High-Performance Liquid Chromatography1 
2.1 Introduction 
The functions of carnitine make it an important compound in lipid metabolism, and studying 
the composition of the carnitine-ester pool can add valuable information to our understanding 
of metabolism. Indeed, metabolism of carnitine has been studied extensively with regard to its 
role in infant nutrition (Tibboel et al. 1990), ketogenesis (Bohles & Akcetin 1987, Brass & Beyerinck 
1988), aciduria (Yount et al. 1989) and metabolic disorders involving oxidation of fatty acids, 
such as acyl-CoA dehydrogenase deficiencies (Harpey etal. 1987). The carnitine profile in tissues 
and plasma can function as an indicator of steps limiting the oxidation of fatty acids. Accumulated 
acyl-CoA esters are converted to carnitine esters, which can be excreted into the cytosol and can 
enter the plasma pool. Plasma carnitine esters are incompletely reabsorbed in the kidney, resulting 
in the excretion of these esters in urine (Olson & Rebouche 1989). Determination of the composition 
of the urinary or plasma carnitine esters can therefore provide information about the steps in oxidation 
which may be limiting. 
Currently available methods to analyze the different carnitine esters are, however, limited. 
A commonly used assay is the radio-isotopic exchange assay (Cederblad & Lindstedt 1972). While 
this method is adequate for crude separations of free, acid-soluble (short- and medium-chain) and 
acid-insoluble (long-chain) acyl-carnitines, it is incapable of distinguishing specific carnitine esters 
that are of interest in metabolic studies. 
Carnitine esters have been analyzed using radio-isotopic exchange, followed by HPLC separation 
and quantification with a 8-flowmonitor (Schmidt-Sommerfeld etal. 1989) .The general principle 
of this method involves the incubation of the sample with radiolabeled carnitine and carnitine 
acyltransferase, allowing the radio-active carnitine to exchange with the carnitine from the carnitine 
esters. The composition of the carnitine esters is determined by HPLC, coupled with an in-line 
8-flowmonitor which results in a radiochromatogram depicting the composition of the different 
'Data as presented in this chapter has been published, together with Chapter 3, in the Journal 
of Chromatography, Biomedical Applications 584:157-165 (1992) © Elsevier Science Publishers 
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esters. If the radiolabeled carnitine exchanged with all esters to a similar extent, this method would 
yield good results. Unfortunately, carnitine acetyltransferase (B.C. 2.3.1.7) which is commonly 
used for this assay, is not sufficiently active toward long-chain acyl-carnitines to obtain quantitative 
yields, nor do medium-chain acyl-carnitines and branched-chain acyl-carnitines yield quantitative 
information without inclusion of appropriate standards. Another confounding issue is the presence 
of an acyl-carnitine hydrolase associated with commercial preparations of carnitine-acetyl-transferase, 
which results in the breakdown of acyl-carnitines (Di Lisa et al. 1992). Although this method 
is extremely sensitive, these complications make it of limited applicability. 
Other methods to quantify acyl-carnitines have been reported which use HPLC separation followed 
by UV detection of derivatized acyl-carnitines (Minkler et al. 1990, Bhuiyan & Bartlett 1988). 
The derealization procedure employs phenacyl reagents which react with the carboxyl group of 
carnitine, creating a UV-absorbing chromophobe group. Although these methods do not have 
the limitation imposed by the limited chain-length specificity of commercial acyl-carnitine acetyl 
transferase, the use of complex derivatization reagents, ternary gradients or atypical columns prompted 
us to develop a simplified method. 
The objective of this paper was therefore to describe a method to analyze carnitine esters using 
commonly available equipment and chemicals. 
2.2 Material and Methods 
2.2.1 Chemicals 
Biosafe II scintillation cocktail was obtained from Research Products International (Mount 
Prospect, IL). 14C-carnitine was purchased from American Radiolabeled Chemicals Inc. (St. Louis, 
MO). Methanol (HPLC grade) was purchased from Baxter Healthcare Corp. (Muskegon, MI). 
Phenacyl-8 was purchased from Pierce (Rockford, IL). Acetonitrile (HPLC grade) was from Fisher 
(Fairlane, NJ), and ninhydrin was obtained from Beckman (Palo Alto, CA). All other chemicals 
and the Kieselgel 60 were supplied by Sigma (St. Louis, MO). Vacutainers were obtained from 
Becton Dickenson and Company (Rutherford, NJ). 
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2.2.2 Equipment 
A Beckman system Gold HPLC was used (Beckman, Palo Alto, CA). The system consisted 
of two HOB pumps, a model 406 analog interface and a model 166 variable wavelength UV detector. 
The system was equipped with a model 507 autoinjector with a 50 /xl injection loop. The column 
used was an Ultrasphere C18-IP column (5 /-cm particle size, 25*0.46 cm, Beckman) with a cartridge 
system guard column (Absorbosphere HS C18, 5 pm particle size, Alltech, Deerfield, IL). To 
accommodate three eluents, pump A was equipped with a three-way switching valve (General 
Valve, Fairfield, NJ), connected with a 12 volt power supply (Radio Shack, Tandy Corp., Fort 
Worth, TX), controlled by a relay in the 406 module (using a second 3 volt power supply and 
a relay). The valve was positioned so as to switch solvents at the inlet line of the pump. From 
the same pump A, the pulse dampener (6 ml void volume) was removed to reduce the volume 
between the pump and the injector (final volume was approximately 4 ml). 
To verify retention times of phenacyl carnitine-esters and to determine recovery of 14C-carnitine, 
a model 265 8-flowmonitor was used (Radiomatics, Tampa, FL). Fractions containing radioactivity 
were collected using a model 204 fraction collector (Gilson, Middleton, WI) and quantified using 
a model LS6000IC liquid scintillation counter (Beckman). 
2.2.3 Isolation of carnitine esters from plasma samples 
Carnitine esters (including free carnitine and 7-butyrobetaine) were isolated from plasma using 
a methanol extraction procedure modified after Minkler etal. (1990). The isolation and derivatization 
procedure is summarized in Fig. 2.1. This procedure can be used to isolate carnitine esters from 
liver as well (unpublished data). 
The internal standard (hexanoyl-carnitine or 14C-carnitine) was added to a known amount of 
plasma (250 /*!). The plasma was extracted with 5 volumes of 100% methanol and centrifuged 
at 30,000 g in a 2 ml microcentrifuge tube (non-siliconized). The supernatant was transferred 
into another vial, and 50 pi of ninhydrin was added. This mixture was evaporated to dryness using 
a model AS160 speedvac (Savant, Farmingdale, NY) allowing the ninhydrin to react with amino 
acids contained in the methanol extract. The methanol-soluble products were reconstituted in 1 
ml 100% methanol, and recentrifuged if cloudy. The methanol fraction (supernatant) was then 
loaded onto a 1 ml silicagel column (Kieselgel 60) contained in a pasteur pipet, and washed 3 
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times with a volume of methanol equal to the column volume. Carnitine esters were subsequently 
eluted using 1.25 ml of a mixture of methanol:water:acetic acid (MWA, 50:45:5 v/v/v) into a 
glass vial. The MWA fraction was then evaporated to dryness. 
The efficiency of the isolation procedure was assessed by adding a known amount of 14C-carnitine 
to the plasma samples before methanol extraction. In subsequent steps of the isolation procedure 
"waste" was collected, and radio-activity in this waste was determined. 
2.2.4 Derivatization procedure 
Acyl-carnitines were derivatized using commercially available phenacyl-bromide which reacts 
with thecarboxyl group of carnitine forming a phenacyl-ester (Durst etal. 1975). The dried MWA 
fraction was reconstituted in (in the order specified): 20 pi H20,0.1ml phenacyl-8 (0.1M phenacyl-
bromide and 0.005 M crown ether in acetonitrile) and 0.9 ml acetonitrile. This mixture was either 
heated at 80°C under vigorous stirring or sonicated at 60°C in an ultrasonic water bath (model 
3200, Branson, Danbury, CT). Similar derivatization efficiencies of 14C-carnitine were obtained 
from each procedure. 
The reaction mixture was evaporated to dryness, and the phenacyl-carnitine esters were 
reconstituted in 500 pi of a mixture of acetonitrile and water (25/75 v/v). Up to 50 pi of this 
mixture was injected into the HPLC. 
The efficiency of derivatization was determined based on recovery of 14C-carnitine and measured 
as the percentage of radioactivity associated with the UV peak corresponding to phenacyl-carnitine, 
compared to total radio activity per injection. Under ivatized carnitine does not co-elute with deriva-
tized carnitine. 
To allow quantification of phenacyl-carnitine esters, 14C-carnitine and 14C-hexanoyl-carnitine 
of known specific activity were derivatized and chromatographed. The peak area and the radio-activity 
associated with the corresponding peaks was determined, and the absorption area per nmol of 
phenacyl-carnitine ester was calculated (analogous to a molar extinction coefficient). 
To verify that the isolation and derivatization procedure yielded similar results for free carnitine 
and medium-chain acyl-carnitines, the recovery of exogenous 14C-carnitine and hexanoyl-carnitine 
from plasma samples was determined. 
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2.2.5 Chromatography 
A constant flowrate of 1.6 ml/min was utilized, which resulted in a head pressure ranging 
from 1700 to 2500 PSI over the course of the gradient employed. Three eluents were used with 
the following composition (by volume): 
I) ACN/H20: 70% acetonitrile and 30% water 
II) H20: 100% water 
III) ACN/TEAP: 80% acetonitrile, 20% water, .8% triethylamine, 0.64% phosphoric acid 
All eluents were passed through a 0.2 pm filter (Anodisk 47, Alltech) and degassed using 
an Alltech filter apparatus. The water used was distilled and deionized (Barnsted 4-module E-pure 
system, Barnsted, Dubuque, IA). 
The gradients are presented graphically in Fig. 2.2. The ACN/H20 eluent (100% I) was used 
to equilibrate the column and was maintained until 1 min after an injection was made (dependent 
on the void volume of the system between switch valve and column; for our system this was 
approximately 4 ml). One min after injection, the switch valve was activated on pump A, causing 
a flow of 100% water (eluent II). The acetonitrile remaining in the system was sufficient to elute 
all excess derivatization agent. In our experience, extending eluent I for longer duration caused 
free and acetyl-carnitine phenacyl-esters to co-elute in the void volume. 
Eluent II was subsequently maintained at 100% for 5 min. A shorter time shifted the free carnitine-
and acetyl-carnitine derivatives to a shorter retention time, and resulted in very poor peak shapes. 
Times of 2 min, however, resulted in good peak shapes for carnitine- and acetyl-carnitine derivatives, 
but not for the medium-chain ester derivatives. 
Six min after injection, a gradient was initiated, delivered through pump B, with the ACN/TEAP 
eluent (III) initially at 15 %. This was increased linearly over a 25 min time period to 100% (replacing 
eluent II). Thirty-six min after the injection, ACN/TEAP (III via pump B) was switched to 100% 
ACN/H20 (eluent I via pump A). The switch valve was typically deactivated 25 min after injection 
such that heat produced by the switch valve was not a problem. The system was re-equilibrated 
for 19 min; injections could be made at 55 min intervals. 
This method was optimized for short- and medium-chain carnitine esters (C2-C10) and tested 
up to palmitoyl-carnitine. Preliminary analyses indicated that long-chain carnitine esters were 
not present at detectable levels in samples used for this and similar studies. Extending the 100% 
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ACN/TEAP period elutes longer-chain esters. 
Phenacyl-carnitine esters have a maximum UV absorption at 245 nm (based on spectral analysis 
obtained with a scanning Gilford Response II spectrophotometer, Ciba Corning Diagnostics, Oberlin, 
OH). Therefore, the detector was programmed to monitor absorbance at 245 nm. Acetonitrile 
and triethylamine absorbed at 245 nm, and this resulted in a gradual rise in baseline with the 
progression of the gradient. This baseline shift could be reduced by using a higher wavelength, 
e.g. 254 nm, but this results in a 20% decrease in sensitivity. 
2.2.6 Elution profile of carnitine esters 
Retention times of different carnitine esters were determined in order to identify peaks in 
chromatograms obtained from plasma samples. Carnitine esters were either purchased or synthesized 
according to the following procedure. CoA esters (0.5 mM) were suspended in a 100 mM TRIS 
(tris(hydroxymethyl)aminomethane) buffer (pH 8.0) containing 1 mM of L-carnitine (plus '^-carni-
tine). To this mixture was added carnitine acetyl-transferase in order to convert the CoA esters 
to carnitine esters. 
The eluticn profile of 7-butyrobetaine (deoxycarnitine) and trimethyllysine was also evaluated. 
Both components are precursors for the de novo synthesis of carnitine and have been detected 
in plasma (Rebouche et al. 1986). The addition of ninhydrin during the purification of carnitine 
esters destroys trimethyllysine; therefore, ninhydrin should be omitted for the quantification of 
total carnitine precursors. 
2.3 Results 
A graphic summary of the isolation procedure as well as the losses of 14C-carnitine internal 
standard in the subsequent steps is given in Fig. 2.1.14C-carnitine was lost in the methanol precipitate 
(10.9 ± 0.3 % of initial ,4C present), in the waste-effluents from the silicagel column (2.7 ± 4.5 %) 
and in non-specified losses (1 %; transfer pipettes, remnants in vials). The overall percentage of 
carnitine recovered in the phenacyl-carnitine peak was 79.9 ± 6.7%. 
The efficiency of derivatization was 94.2 ± 4.1% (n=6). The recovery of 14C-carnitine and 
hexanoyl-carnitine (UV) correlated with anr2 of 0.95, and the absorption area per nmol of carnitine 
(7.42) and hexanoyl-carnitine (7.70) were not statistically different (p>0.1). 
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Fig. 2 . 1 . Graphic summary of the isolat ion procedure for acyl-carni t ines from plasma 
samples, and the loss of "C-carni t ine in the subsequent s teps of the i so l a t ion 
procedure (ppt = p r e c i p i t a t e , spt = supernatant , MeOH = methanol, MWA = methanol/ -
water/ a c e t i c acid (50/45/5 v / v / v ! ) . 
The complete elution profile of all tested esters and 7-butyrobetaine is given in Fig. 2.2. This 
elution profile is actually a composite of 2 chromatograms since the reaction conditions used to 
synthesize the acyl-carnitines caused a broad carnitine peak, overlapping 7-butyrobetaine (see 
dashed line). To illustrate the separation of carnitine esters, another chromatogram (10-15 min) 
with carnitine, 7-butyrobetaine, and acetyl-carnitine is overlaid. 
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20 
Retention time (min.) 
Fig. 2.2. Elution profile of 
phenacyl esters of carnitine, 
•y-butyrobetaine and various 
carnitine esters, identified 
by numbers representing the 
chain-length of the acyl-group 
(i4=isobutyryl-carnitine, 
i5=isovaleryl-carnitine) . The 
Roman numbers and dotted lines 
represent the eluents used to 
obtain the chromatogram (see 
text for details). 
In Fig. 2.3, the retention time observed for the phenacyl esters of acyl-carnitines is regressed 
as a function of the chain-length of the acyl group. A linear relationship was observed for the 
straight-chain acyl-carnitines. 
6 8 10 
Chain length 
Fig. 2.3. Retention time (in 
min and in multiples of k') of 
phenacyl esters of acyl-
carnitines as affected by the 
chain-length of the acyl-group 
(the crosses denote from left 
to right: free carnitine, y-
butyrobetaine, isobutyryl-, 
and isovaleryl-carnitine, all 
of which were not included in 
the regression equation). 
Two chromatograms, obtained from plasma-sample analysis (equivalent to approximately 20 
/il plasma) for carnitine esters are given in Fig. 2.4. Both chromatograms show the presence of 
free carnitine, the carnitine precursor 7-butyrobetaine, acetyl-carnitine, and C4-carnitine. In the 
chromatogram obtained from a pig fed tri-C7 (Fig. 2.4B), propionyl-carnitine and possibly valeryl-







Retention time (min) 
Fig. 2.4A and B. Samples of 
c a r n i t i n e - e s t e r plasma prof-
i l e s obtained from pigs 4 h 
a f t e r feeding 6 ml of medium-
chain t r ig lycer ides containing 
(saturated) f a t t y acyl-chains 
of .6 (A) or 7 carbons (B) . 
2.4 Discussion 
The method presented provides a powerful tool to analyze carnitine esters. Because it employs 
standard reversed-phase column chemistry and commercially available reagents, this method is 
easy to implement in laboratories using an HPLC. The observation that odd-chain MCT can give 
rise topropionyl-carnitine in plasma (Fig. 2.1 A) and (abnormally) elevated 7-butyrobetaine (Fig. 
2.3) in one litter of pigs illustrates the importance of a method which can distinguish between 
different carnitine esters in plasma samples and, therefore, detect potential abnormalities in the 
profile. Several metabolic disorders can be characterized via analysis of the carnitine profile as 
observed in plasma (Harpey et al. 1987, Roe et al. 1985). 
The isolation procedure of plasma carnitine esters proved to be effective for both free and 
medium-chain acyl-carnitines. Stearic hinderance of the carboxyl group of (medium-chain) acyl-carni-
tines by the fatty-acid chain, which could possibly prevent efficient derivatization, as mentioned 
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by Minkler (Minkler et al. 1984) was not observed to be a problem using phenacyl-bromide as 
a derivatization agent. 
The linear dependence of the retention time of acyl-carnitine derivatives on chain-length of 
the acyl group (Fig. 2.3) suggests that the hydrophobicity of the acyl-group is an determining 
factor in the elution profile (given the use of a linear gradient). 
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Chapter 3. The effect of feeding MCT of varying chain-length on the carnitine ester profiles 
in newborn pigs2 
3.1 Introduction 
The role of L-carnitine (fi-hydroxy-7-trimethylaminobutyric acid) in the transport of long-chain 
fatty acids across the inner mitochondrial membrane has long been acknowledged. Carnitine replaces 
the CoA group of acyl-CoA by the action of carnitine acyl-transferase. The formed acyl-carnitine 
is then transported across the inner mitochondrial membrane by carnitine acyl-translocase, and 
the carnitine is again replaced by a CoA, forming acyl-CoA (Fritz & Schultz 1965). 
More recently, carnitine has been shown to have a similar role in the export of the products 
of 8-oxidation from the peroxisomes (Mannaerts &Debeer 1982). Reboucheetal. (1990) proposed 
that carnitine has a role in releasing mitochondrial CoA from acyl-CoA when the free CoA supply 
becomes limiting due to activation and subsequent accumulation of metabolites in the mitochondrion. 
Carnitine might act as a buffer to the mitochondrial acyl-CoA/CoA ratio by translocating excess 
acyl-groups into the cytosol. 
The carnitine profile in tissues and plasma can function as an indicator of steps limiting the 
oxidation of fatty acids. Accumulated acyl-CoA esters are converted to carnitine esters, which 
can be excreted into the cytosol and can enter the plasma pool. Plasma carnitine esters are 
incompletely reabsorbed in the kidney, resulting in the excretion of these esters in urine (Bremer 
1983). Determination of the composition of the urinary or plasma carnitine esters can therefore 
provide information about the steps in oxidation which may be limiting. 
Carnitine is considered to be a conditionally essential nutrient, especially for the neonate. This 
nutritional aspect of carnitine has been widely accepted when long-chain fatty acids (> C14) provide 
the majority of the energy for the neonate (Bremer 1983). Recent evidence, however, has suggested 
that carnitine supplementation might also be important in neonates fed medium-chain triglycerides 
(MCT, containing C6 to C12 fatty acids). Rebouche et al. (1990), although not proposing a beneficial 
effect of supplemental carnitine, reported the accumulation of medium-chain acyl-carnitine intermedi-
2Data as presented in this chapter has been published, together with Chapter 2, in the Journal 
of Chromatography, Biomedical Application 584; 157-165 (1992) ® Elsevier Science Publishers 
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ates in plasma after feeding infants with MCT, suggesting a role of carnitine in the oxidation of 
these medium-chain fatty acids. 
The objective of this chapter was to determine which acyl-carnitines were affected by feeding 
MCT to piglets. Since no easy to use, accurate method was available for this analysis, a new 
HPLC method was developed for this assay. This method is described in Chapter 2. 
3.2 Materials and Methods 
To determine the effect of feeding MCT on the plasma carnitine profile, plasma samples were 
obtained from 16 MCT-fed pigs. The pigs were removed from the sow 24 h after birth (4 pigs 
per litter), and were fasted for an additional 4 h while housed in pens maintained at 32°C. MCT 
oils consisting of different chain-length (saturated) fatty acids (4, 5, 6 or 7 carbons, indicated 
as tri-C4, tri-C5, tri-C6 or tri-C7 respectively) were subsequently fed via gastric intubation in 
doses of 6 ml so that all 4 pigs per litter received MCT oil containing a different chain-length 
fatty acid. Blood samples were obtained via jugular venipuncture using heparinized vacutainers 
at 0, 1, 2, 4, and 8 h after oral gavage. Plasma was obtained following centrifugation at 4°C 
and was stored at -20°C until analyzed. The samples used were obtained in the course of another 
study (Wieland et al. 1992). 
The data were analyzed by the analysis of variance procedure using SAS (1982) according 
to a split-plot design, blocked by litter (Steel & Torrie 1980). 
3.3 Results 
The acyl chain-length of the MCT fed to the piglets significantly affected the concentration 
of free carnitine as well as the concentration of propionyl-carnitine. Propionyl-carnitine was undetect-
able in animals fed even-chain MCT, as well as at time 0 in alljreatments. In animals fed odd-chain 
MCT (tri-C5 or tri-C7), propionyl-carnitine increased with increasing oxidation rate of the odd-chain 
fatty acids and declined in a similar fashion as the oxidation rate declined (see Fig. 3.1A). 
Plasma free carnitine concentrations varied considerably during the sampling period. A significant 
chain-length effect (p < .06) as well as a significant time effect was observed (p < .05). Odd-chain 
MCT invoked a higher plasma free carnitine concentration compared to even-chain MCT. A signifi-
cant increase in plasma carnitine concentration was observed 1 h after gastric intubation, while 
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no increase was observed 2 h after gastric intubation (plasma fatty acid concentrations peaked 
between 1 and 2 h (Wieland et al. 1992). 
2 4 6 
Time after oral gavage (h) 
Fig. 3.1. The effect of feed-
ing MCT of varying chain-
lengths (tri-C4 through 
tri-C7) on the concentrations 
of propionyl-carnitine (A) and 
free carnitine (B) in plasma 
of newborn pigs. Propionyl-
carnitine: time effect p<.01 
and chain-length effect p 
<.05; free carnitine: time 
effect p<.0l and treatment 
effect p<.06), n=3 per mean. 
2 4 6 
Time after oral gavage (h) 
No significant effects were observed in 7-butyrobetaine and acetyl-carnitine esters (p>0.1). 
Acetyl-carnitine varied considerably, and tended to be higher when tri-C6 and tri-C7 were fed; 
but due to the high variation, no significant effects were observed (data not shown). 
The C4-carnitine peak, presumptively identified as butyryl-carnitine, followed a pattern which 
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mirrored the pattern of free carnitine; however, no significant effects were observed (p>0.1, 
see Fig. 3.2). 
A 
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2 4 6 
Time after oral gavage (h) 
Fig. 3 .2 . The effect of 
feeding MCT of varying chain-
length on (A) the concentra-
t ions of y-butyrobetaine and 
acetyl-carni t ine averaged over 
treatments (n=12 per mean) and 
(B) C4-carnit ine in plasma of 
newborn pigs (n=3 per mean). 
Other peaks occurred in the chromatograms, from which the retention time of one peak corre-
sponded with the retention time of C5-carnitine (from pigs fed tri-C7). Due to sporadic co-elution 
of a reagent peak, later identified as originating from the use of dated ninhydrin reagent, the C5-
carnitine peak could not be quantified consistently (Appendix A, Fig. A4). Other peaks were not 
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identified since their retention time did not correspond to the retention time of a saturated, straight-
chain acyl-carnitine. 
With the exception of one litter of pigs, 7-butyrobetaine was low throughout the experiment. 
These animals were not included in the final analysis of the data. Pigs from this litter exhibited 
extremely high concentrations of carnitine precursor (7-butyrobetaine) and relatively low levels 
of free carnitine. No elevation in free carnitine was observed 1 h after oral gavage, while a rise 
was observed in 7-butyrobetaine. Fig. 3.3 shows data averaged over treatments from this litter 
contrasted to data averaged over treatments from the other 3 litters. 
Carnitine iGbb !C2-cam !C3-cam gJCtcam 
Fig. 3.3. The effect of 
feeding MCT on the carnitine 
profile over time. A; averaged 
over 12 pigs (three litters) 
with normal 7-butyrobetaine 
(Gbb) levels or B; averaged 
over 4 pigs (one litter) with 
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Time after oral gavage (h) 
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3.4 Discussion 
The data obtained from pigs fed MCT indicate that MCT feeding does affect the concentration 
of free carnitine in plasma (Fig. 3. IB). The concentration of free carnitine increased 1 h after 
feeding, but dropped to the 0-h level at 2 h. The increase in plasma carnitine at 1 h after feeding 
MCT suggests that the pig has the ability to mobilize carnitine from tissues such as the intestines, 
as suggested by Li et al. (1992). The biological significance of this possible mobilization is unknown, 
but raises the question of whether plasma carnitine is a correct parameter for assessing the carnitine 
status of a subject under certain nutritional and/or disease states. 
The drop in plasma carnitine between 1 and 2 h after feeding MCT might be caused by an 
impaired reabsorption of free carnitine by the kidneys due to the high levels of plasma fatty acids, 
as suggested by Penn et al. (1992) and Stadler & Rebouche (1992). Further experiments are needed 
to determine the exact cause. 
Odd-chain fatty acids (upon 6-oxidation) can yield propionyl-carnitine (as well as valeryl-camitine). 
Propionyl-carnitine was present in the plasma of pigs fed tri-C5 or tri-C7, suggesting that the 
production of propionyl-CoA exceeds the oxidation in certain tissues (Fig. 3.1A). Propionyl-CoA 
is mainly produced within the mitochondria under the conditions employed. The presence of propionyl-
carnitine suggests that carnitine does act as a buffer of the intramitochondrial CoA pool by exporting 
acyl-groups such as propionate. 
The anecdotal observation that one litter of pigs had high concentrations of the carnitine precursor 
7-butyrobetaine and relative low levels of free carnitine suggests that these pigs had a genetic 
deficiency, impairing either the uptake of 7-butyrobetaine by the liver or the synthesis of carnitine 
from 7-butyrobetaine in the liver (Fig. 3.3). A similar condition was previously observed in an 
infant by Dr. S.C. Winter (personal communication). Detailed information on this case is, however, 
lacking as well. 
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Chapter 4. Medium-chain fatty acid oxidation in colostrum-deprived newborn piglets: stimulatory 
effect of L-carnitine supplementation3 
4.1 Introduction 
A major problem in the care of premature and/or small-for-gestational-age infants is the provision 
of sufficient amounts of nutrients, especially energy, to support rapid body weight gain. Under-
development of the gastrointestinal tract makes enteral feeding problematic, and consequently, 
intravenous infusion of nutrients is often employed. A major challenge with intravenous infusion 
of nutrients is to provide sufficient amounts of energy without negative effects on the health of 
the subject, such as fluid overload. Thus, lipid emulsions are often used because of their high 
energy density and low osmolarity (Lima 1989). 
Commonly used lipid emulsions are composed of long-chain triglycerides. However, infusion 
of these lipids is associated with several problems such as hypertriglyceridemia, decreased immunity, 
hepatomegaly and splenomegaly (Bell etal. 1991, Booth 1992). To avoid these problems, triglycerides 
composed of medium-chain fatty acids (MCFA4, which are fatty acids with 6-12 carbons, often 
in combination with long-chain fatty acids) are being used increasingly for both parenteral (Goulet 
et al. 1992) and enteral nutrition (Kelts & Jones 1984, Lima 1989, Bell 1991, Borum 1992). 
Carnitine functions as a cofactor involved in the transport of (long-chain) fatty acid groups 
(after activation to an acyl-CoA) across the inner mitochondrial membrane (Fritz 1968) and has 
also been suggested to have a role in buffering intramitochondrial free CoA by aiding in the export 
of acyl-groups (Siliprandi et al. 1990). Neonates are considered carnitine deficient, which could 
impair their capacity to utilize long-chain fatty acids as a fuel, particulary when fed via total parenteral 
nutrition (Penn et al. 1981). 
Medium-chain fatty acids can passively diffuse through the inner mitochondrial membrane 
and can be activated intramitochondrially, thereby eliminating the need for carnitine as a cofactor 
for entrance into the site of oxidation. Although in vitro evidence indicates that carnitine stimulates 
the oxidation of MCFA in muscle (Aas 1971, Groot & Hulsmann 1973, Otto 1984), MCFA are 
3This chapter has been published in the Journal of Nutrition, 123: 1531-1537 (1993) 
o American Institute of Nutrition 
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commonly fed to (premature) infants without supplemental carnitine (Lima 1989, Booth 1992). 
The objective of the research reported herein was to determine whether the assumption that MCFA 
oxidation is carnitine independent is appropriate in the neonatal pig model (Shenai et al.1983, 
Baltzell et al.1987, Hannon et al.1990). 
4.2 Materials and methods 
4.2.1 Animals 
Newborn, colostrum-deprived pigs (commercial crossbreds, avg. weight: 1.46±0.34 kg) were 
obtained from the Swine Research Center of the University of Illinois (trial 1 and 2) and from 
a commercial swine farm (trial 3 and 4). The animal protocols were approved by the University 
of Illinois Laboratory Animal Care Advisory Committee and were in accordance with the "Guide 
for the Care and Use of Laboratory Animals" (NRC 1985). 
The animals (littermates within a trial) were removed from the sow immediately after birth, 
and placed in a heated box (30-35 °C). Using a minor surgical procedure, an argyle catheter (3% 
french, Sherwood Medical, St. Louis, MO) was inserted into an umbilical artery as described 
by Benevenga et al. (1992) using general halothane anaesthesia (Halocarbon Laboratories, North 
Augusta, SC) in combination with local lidocaine anaesthesia (Anthony Products, Arcadia, CA) 
of the umbilicus. This catheter was inserted 22 cm into the aorta to a position near the heart (as 
verified by X-ray photography) and was used for infusion of [l-14C]-medium-chain fatty acids. 
After recovery from the anaesthesia (l-2h), piglets were randomly placed into one of four 
respiration chambers consisting of an acrylic tube (15 cm diameter*45 cm long), designed after 
those described by Benevenga et al. (1992). A heat pad on the outside of the chambers maintained 
the floor temperature in the chambers at 35°C. The chambers (Fig. 4.1) were mounted onto a 
metal frame and connected to an air inlet containing a sodasorb canister to remove incoming C02. 
The volume of air passing through each chamber (2 L/min) was controlled by flowmeters (Cole 
Parmer Instrument Co., Niles, IL). Air exiting the chambers was diffused through one of 2 columns 
containing 75 mL of a 1.8 N sodium-hydroxide solution to trap expired 14C02. The sodium-hydroxide 
solution was replaced at twenty min intervals after switching the air flow to the alternate columns. 
This allowed for continuous collection of all C02. Preliminary studies verified that under these 
conditions, in excess of 95% (102.5±3.2%)of the expired C02 was trapped via this system. Recovery 
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was assessed using continuous infusion of a sodium bicarbonate (1 mmol/min) solution into a 
shallow pan mounted within the respiration chamber. The infused bicarbonate was mixed with 
excess HC1 via a mixing T in the chamber resulting in the release of C02. Infused C02 (as 
bicarbonate) was recovered in the sodium-hydroxide-containing columns and analysed as described 
below. 
Fig. 4 . 1 . Schematic view of 
the apparatus used to col lec t 
expired C02 and to house the 
p i g l e t s . Using a vacuum pump 
(A), a i r (2 L/min) was f i r s t 
drawn through a column of 
sodasorb (B), subsequently 
through the chambers in which 
the p i g l e t s were housed (C) , 
a f t e r which the a i r was passed 
through columns containing 
sodium-hydroxide (D). 
An infusion line was connected to the arterial catheter of each pig and connected to an eight-
channel peristaltic infusion pump (model 07524, Cole Parmer Instrument Co., Niles, IL) which 
allowed for continuous delivery of infusate from I.V. bags (Baxter Healthcare Corp, Deerfield, 
IL). Upon infusion of the fatty acid solution, the piglets would generally sleep, but could be aroused 
easily by moving the chamber. 
4.2.2 Infusion protocol 
Pigs in trials 1 and 2 were infused for a total of 9 h and pigs in trials 3 and 4 for 12 h. During 
this time period, a constant infusion of [1-14C]-MCFA (appr. 0.05 MBq/h; octanoic acid (C8): 
American Radiolabeled Chemicals, Inc. St. Louis, MO; heptanoic acid (C7) and decanoic acid 
(CIO): Sigma Chemical Co., St. Louis, MO) diluted with corresponding non-radioactive MCFA 
(Sigma Chemical Co., St. Louis, MO) was maintained. The infusion rates were varied between 
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pigs as per Table 4.1. Solutions were made iso-osmotic with NaCl (308 mmol/1), and the p H 
was adjusted to 7.4. Volume delivery was approximately 25 mL/h throughout the trial. 
Table 4.1. Treatments for trials 1-4 in which, for each trial, 4 newborn, colostrum-
deprived piglets were used. 
MCFA infused 
Energy infusion (energy 
provided2 /MR3* 10 0) 
Carnitine dose4 
(Aimol/(h-kg0-75)) 





































1; One C7 infused animal served as the no-carnitine control. 
2; The energy content of the different chain-length fatty acids was calculated 
based on ATP equivalent per mole (C7: 52 ATP, C8: 61 ATP, C10: 78 ATP), and 
that the synthesis of 1 mole of ATP required 73.3 kJ metabolizable energy. 
3
,- The energy content of the infusates are expressed relative to the anticipated 
metabolic rate (MR) of the piglets (200 kJ/(d-kg°-75)) . 
*; The carnitine doses were based on estimated normal carnitine intake via milk 
consumption (approximately 10 iimol/ (h-kg°-7S), Kerner et al. 1984, Den Hartog 
et al. 1987)). 
To ensure maximum sensitivity in detecting possible carnitine effects, each piglet served as 
its own control. To accomplish this, an initial carnitine-free infusion period was compared to 
a subsequent period in which carnitine was supplemented. Specifically, the first 5 h (trial 1 and 
2) or 7 h (trial 3 and 4) of each infusion was used to determine the rate of fatty acid oxidation 
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in the absence of exogenous carnitine (carnitine-free infusion period). Previous research (Odle 
et al. 1992) showed that 5 h was sufficient to predict the steady-state MCFA oxidation rate. After 
5 or 7 h of MCFA infusion, a primed co-infusion of L-carnitine (Lonza AG, CH4002, Basel, 
Switzerland) was initiated (carnitine infusion period) to determine if carnitine addition could deviate 
the fatty acid oxidation rate from the trend as determined based on the carnitine-free infusion 
period. Carnitine infusion rates (see table) were based on the amount of carnitine present in colostrum 
normally consumed by pigs (approximately 10 pmol/h, Kerner et al. 1984, Den Hartog et al. 
1987). 
Three pigs did not receive any carnitine in order to validate that the extrapolation/modeling 
approach accurately predicted the fatty acid oxidation rates in the "carnitine" infusion period. 
The other pigs received a bolus injection of 12.5, 25 or 50 pmol carnitine (2.5 times the hourly 
doses) dissolved in 1 mL physiological saline at the start of the carnitine infusion period. During 
the carnitine infusion period, these pigs then received either 5,10 or 20 jumol carnitine/(h-kg0/75) 
respectively, which was mixed with the MCFA infusate. 
After the infusions were completed, pigs were anaesthetized using an i.v. injection of pentobarbital 
and killed using an intracardial injection of saturated KC1. 
4.2.3 Analysis 
Sodium-hydroxide samples were analyzed for C02 as described by Benevenga et al. (1992). 
Based on the ratio of the specific radioactivity of the expired C02 and the specific radioactivity 
of the infused MCFA, an instantaneous fatty acid oxidation rate (FA-OR = MCFA-derived C02/total 
CO2*100) was calculated, assuming that the fate of the [1-14C] carbon represented the fate of all 
carbons within the fatty acid molecule. The measured C02 radioactivity was not corrected for 
the lag of expiration of C02 due to dilution in the body pool. This results in an underestimation 
of the actual oxidation rates of the infused [l-14C]-medium-chain fatty acids. This inaccuracy does 
not, however, pose a problem for the interpretation of the results which evaluated the relative 
change in fatty acid oxidation rate elicited by carnitine supplementation. 
The data obtained during the carnitine-free infusion period were fitted to a single pool exponential 
curve which was determined by Benevenga et al. (1992) to accurately model the data: 
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FA-OR = A*(l-e-k(t"ts>) 
where: FA-OR=fatty acid oxidation rate (%)=(MCFA-derived C02/total CO2*100) 
A=asymptotic maximal FA-OR at t=infinity (%) 
k=fractional rate constant (min'1) 
t=time (min) 
to=lag of start of oxidation of MCFA (min) 
To determine the carnitine response, the curve obtained was extrapolated to the carnitine infusion 
period, and the estimated values of MCFA oxidation were compared with the actual oxidation 
rates observed. The differences between observed values and estimated values were determined 
(carnitine response) and a paired t-test was used to test whether the difference was greater than 
zero. 
4.3 Results 
Metabolic rates in this study were calculated assuming that glucose (464 kJ/mol C02) and 
MCFA (559kJ/mol CO%) were the primary fuels, and were found to be 197±26 kJ/(d-kg0-75), 
which was independent of body size and age (p> 0.1, data not shown). The oxidation rate of fatty 
acids (as a function of infusion rate) was independent of the age of the animals, and the carnitine 
response (expressed as a function of the infusion rate) in the 24 h age group showed a significant 
response which was similar (p>0.1) to the combined data. Therefore, data were pooled accross 
age groups. 
In Fig. 4.2, the oxidation rate of MCFA (asymptotic maximal FA-OR at t=infinity) is expressed 
as a function of infusion rate of MCFA, both scaled as a percentage of the metabolic rate of the 
animal. Based on these data, oxidation of MCFA accounted for 40% of the carbon (p<0.01), 
assuming that the fate of the [1-14C] carbon represents the fate of all carbons in the fatty acid 
molecule. 
Two example graphs illustrating the time course of MCFA oxidation to C02, as well as the 
C02 production are shown in Fig. 4.3. The top panel represent the data from a pig infused with 
carnitine in the carnitine infusion period, while the bottom panel represents the data from a control 
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Fig. 4.2. The asymptotic 
maximal fatty acid oxidation 
rate of MCFA in newborn, 
colostrum-deprived piglets, as 
a linear function of the 
infusion rate, both expressed 
as energy equivalents as a 
percentage of the metabolic 
rate (MR) of the recipient. 
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Fig. 4.3. Sample graphs of the 
fatty acid oxidation rate 
(FA-OR=MCFA-derived C02/total 
CO2*100) and the C02 production 
as a function of time (pmol/ 
(kg°-75-min)) of two of the 16 
pigs receiving variable 
amounts of carnitine and MCFA 
(see table 4.1). The squares 
represent measured values, 
while the solid line is the 
curve as fitted to the fatty 
acid oxidation rate; the 
dashed line is the extrapo-
lation of this curve assuming 
no carnitine effect. The graph 
in the upper panel is from a 
piglet infused with MCFA at 
111% of its metabolic rate, 
and carnitine was supplemented 
at 20 /miol/(h-kg0-75) ; the 
increase in FA-OR was 3.87 
(p<0.05). The graph in the 
lower panel is from a piglet infused with MCFA at 57% of its metabolic rate, but 
no carnitine was supplemented; the increase in FA-OR was 0.07 (p>0.10) . The arrow 











The response to exogenous carnitine was independent of the level of carnitine infused (data 
not shown). It may be that the priming doses administered were sufficient to maximize the response. 
The increase in FA-OR due to exogenous carnitine supplementation was, however, a linear function 
of the infusion rate of fatty acid (p<0.01, Fig. 4.4). Of the 10 animals infused with carnitine 
and MCFA at a rate providing more than 75 % of their metabolic rate, 8 responded with a significant 
increase (p <0.1 , n= 1; p<0.05, n=7) in FA-OR (up to a 20% relative increase in the fatty acid 
oxidation rate). 
Fig. 4.4. The carnitine 
response expressed as a linear 
function of the fatty acid 
infusion rate. The carnitine 
response was calculated as the 
increase in MCFA oxidation 
rate (FA-OR) during the 
carnitine infusion period as 
compared to the curve extrapo-
lated from carnitine-free 
infusion period. The FA-OR is 
expressed as the energy 
derived from fatty acid 
oxidation as a percentage of 
the (calculated) metabolic 
rate (MR) of the piglet. Each 
point represent the average increase in FA-OR during the carnitine infusion period 
as calculated based upon data from one pig. 
100 125 
Infusion rate (96 of MR) 
150 175 
4.4 Discussion 
The metabolic rate of newborn, colostrum-deprived pigs is lower than the metabolic rate of 
0-24 h fed and colostrum-deprived pigs as reported by others (Noblet & Le Dividich 1981, Curtis 
1970). Although the measurements made do not allow for exact determination of metabolic rates, 
the assumption that all CO2-carbon is derived from glucose and MCFA allows for fairly accurate 
estimation of metabolic rates since newborn piglets have a low protein turnover and limited amounts 
of non-structural endogenous lipids (Mellor & Cockburn 1986). According to our data, the basal 
metabolic rate of newborn, colostrum-deprived pigs was calculated to be 197 ± 26 kJ/(d-kg0-75), 
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which is in agreement with data from Mellor and Cockburn (1986). 
Of the MCFA infused, 40% could be recovered as C02. This value, which is low assuming 
that MCFA cannot be readily stored as medium-chain triglycerides (Bach & Babayan 1982), is 
in agreement with data from Sulkers et al. (1989) and less than the 60% as reported by Odle et 
al. (1992). The fate of the remaining 60% of the carbon is not clear, but other research has suggested 
that a substantial portion of the MCFA can either be chain-elongated or converted to long-chain 
fatty acids via lipogenesis after breakdown to acetyl-CoA (Zurier et al.1967, Reeve & Franks 
1968, Sarda et al. 1987). Zurier et al. (1967) investigated the effect of feeding MCT to rats with 
a portacaval shunt, and concluded that "striking increases in proportions of MCT in adipose tissue 
were noted", which was not observed to a similar extent in control (no portacaval shunt but MCT-fed) 
animals. This suggests that the site of entrance into circulation is a major determinant for the 
extent of reesterification of the MCFA. In our experiment, MCFA were infused into the aorta, 
which results in MCFA being transported to all tissues, dependent on blood flow distribution, 
as was the case in Zuriers' experiment. 
Another determinant in the fate (oxidation versus lipogenesis) of MCFA might be the site of 
activation in liver. According to Aas (1971) and Groot & Hulsmann (1973), liver mitochondria 
contain an intramitochondrial medium-chain acyl-CoA synthetase. However, in determining extra-
mitochondrial versus intramitochondrial activation, it was observed that a major portion of the 
MCFA were activated outside of the matrix (Aas: aproximately 75%, Groot & Hulsmann: 
approximately 40%). Low long-chain fatty acid oxidation observed in vitro suggests that uptake 
of acyl-CoAs into the mitochondria is inhibited, possibly via carnitine palmitoyltransferase I. 
Long-chain fatty acids are, however, actively reesterified by hepatocytes (Girard et al. 1992). 
The site of activation might, therefore, determine if fatty acids are oxidized (intramitochondrial 
activation) or esterified/chain-elongated (extramitochondrial activation). 
Consistent with previous research (Odle et al. 1992), MCFA infusion did not increase C02 
production during the course of infusion (p>0.1, data not shown). This is somewhat surprising 
since MCFA are considered obligatory fuels (Bach & Babayan 1982) and have been shown to 
increase heat production in humans compared to long-chain fatty acids (Seaton et al.1990). The 
reason for this discrepancy is not known. 
Carnitine clearly increased the contribution of fatty acids to total fuel oxidation if fatty acids 
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were infused at levels which could supply more than 50% of the energy need of the piglet. The 
stimulatory effect of carnitine became more pronounced at higher levels of fatty acid infusion. 
The effect of carnitine could be due to the lack of sufficiently developed octanoyl-CoA synthetase 
as reported by Shipp et al. (1982) using guinea-pig liver. The octanoyl-CoA synthetase is the 
enzyme responsible for the intra-mitochondrial activation of medium-chain fatty acids, and a low 
activity of this enzyme would make the oxidation of MCFA dependent on their activation by acyl-CoA 
synthetases on the outer mitochondrial membrane and the endoplasmic reticulum. This would 
make the MCFA oxidation carnitine dependent since acyl-CoA compounds can not diffuse through 
the inner mitochondrial membrane. 
A second possibility for a role of carnitine might be via its involvement in MCFA oxidation 
in extrahepatic tissues. Aas (1971) and Groot and Hulsmann (1973) suggested that no specific 
acyl-CoA synthetase is present in muscle with an optimum activity toward medium-chain fatty 
acids. This would result in the formation of medium-chain acyl-CoAs which have to be transported 
into the mitochondrial matrix involving carnitine, as demonstrated by Groot and Hulsmann (1973) 
using rat muscle mitochondria. The biological importance of this carnitine dependence is generally 
not considered important, which might be warranted due to the low metabolic rate of muscle 
(compared to e.g. liver) in combination with the presumed high levels of muscle carnitine, which 
could prevent metabolic problems when MCFA are oxidized (Negrao et al. 1987). Muscle carnitine 
levels in term and premature infants are, however, low compared with adult controls (Penn et 
al. 1985). Further research clearly needs to adress this issue. 
A third possibility is that the carnitine effect could be mediated by its "buffering" of the 
intramitochondrial acyl-CoA/free CoA ratio via export of acyl-groups after conversion to acyl-
carnitines (Chalmers et al. 1983) which is supported by data obtained from infants fed MCT from 
Rossle et al (1990) and Rebouche et al. (1990). The release of CoA by transfer of acyl-groups 
to carnitine can be regarded as a detoxification, since excess acyl-CoA can inhibit normal 
mitochondrial function with regard to the urea cycle and normal energy production via both the 
Krebs cycle and 8-oxidation (Stumpf et al. 1985, Harpey et al. 1990). The acyl-carnitines can 
subsequently be excreted into the urine. This excretion, although beneficial for the short term, 
can, however, also lead to a secondary carnitine deficiency, obstructing further buffering of the 
CoA pool (Chalmers et al. 1983). The presence of propionyl-carnitine in plasma of newborn piglets 
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fed odd-chain medium-chain fatty acids (Kempen & Odle 1992) confirms that excess acyl-groups 
can be exported from the mitochondrion, since propionyl-CoA under the conditions employed 
is mainly produced by 8-oxidation of odd-chain MCFA, which occurs inside the mitochondrion. 
In conclusion, this research suggests that carnitine does play a role in MCFA oxidation in vivo, 
and opens the question as to whether carnitine should be added to nutrition solutions containing 
MCT or MCFA. 
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Chapter 5. Dicarboxylic acid (DCA) production of newborn pigs infused with medium-chain 
fatty acids (MCFA): effects of valproate and L-carnitine co-infusion 
5.1 Introduction 
Dicarboxylic acids are produced by hepatocytes (Hare & Wahle 1985) when the supply of 
fatty acids to the liver exceeds the capacity for 8-oxidation (e.g. due to a metabolic disorder) and 
reesterification (e.g. in MCFA feeding), leading to the accumulation of fatty acids in the cytosol 
(Sherratt & Veitoh 1984, Cerdan et al. 1988, Mortensen 1986, Draye et al. 1988). The accumulated 
fatty acids can serve as a substrate for w-oxidation which is initiated by the mixed function oxidase 
system (including cytochrome P-450) and results in the oxidation of the w-carbon (methyl-carbon) 
of the fatty acid in a concentration-dependent fashion (Vamecq & Draye 1989). The metabolic 
function of w-oxidation is still unknown but is suggested to be, in conjunction with 8-oxidation, 
the formation of the TCA-cycle intermediate succinate (Mortensen 1992). However, a major (static) 
portion of DCA produced are excreted in urine (after 8-oxidation, Mortensen 1981, Mortensen 
1986). 
Accumulation of fatty acids resulting in DCA production is more likely to occur in subjects 
who are fed or infused with MCFA (Mortensen 1981), partly due to the more rapid route of entry 
(via the portal vene) from the gastrointestinal tract and partly due to the lower rates of reesterification 
in intestines and liver as compared to long-chain fatty acids (Bach & Babayan 1982). In addition, 
several researchers (Rossle et al. 1990, Rebouche etal. 1990) have suggested that MCFA feeding 
might result in the depletion of intramitochondrial free CoA which could impair 8-oxidation and 
because of the resulting increase in fatty acid concentration, in an even greater rise in DCA 
production. Since the use of medium-chain triglycerides (MCT) as an energy source for both enteral 
and parenteral nutrition formulations has surged in recent years (Booth 1992, Borum 1992), the 
concern over the associated production of DCA has also increased (Henderson & Dear 1986, 
Lima 1989, Borum 1992). 
Other conditions exist in which the supply of fatty acids exceeds the capacity of the liver to 
metabolize these fatty acids, for example, when epileptic patients are treated with the anti-convulsant 
drug valproic acid (Mortensen 1992, Triggs etal. 1990). The reason for the increased production 
of DCA in valproate-treated subjects is purportedly related to an intramitochondrial free CoA 
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depletion caused by the activation of valproate which then renders a poorly catabolyzed CoA ester 
(Sherratt & Veitch 1984, Zammit et al. 1989, Rozas et al. 1990, Veitch & Hoof 1990). 
The putative CoA depletion occurring when MCFA are fed or when valproate is dosed can 
be counteracted by carnitine. Carnitine can act as a carrier molecule for the export of activated 
acyl groups (such as valproate and its metabolites) out of mitochondria through carnitine acyl 
transferase II, which liberates CoA. The resulting acyl-carnitine can be excreted into the cytosol 
and ultimately into the urine (Becker & Harris 1983). This excretion of carnitine, however, can 
ultimately lead to a carnitine deficiency (which in itself is known to cause dicarboxylic aciduria, 
Chalmers et al. 1984). 
Previously, we (Kempen & Odle 1993) demonstrated that octanoate oxidation could be stimulated 
in vivo by L-carnitine supplementation in carnitine deficient subjects, thereby illustrating that 
carnitine indeed has a role in MCFA oxidation. The purpose of the experiment described herein 
was to determine the effects of carnitine, MCFA and MCFA+valproate infusion on the dicarboxylic 
acid excretion in carnitine-deficient newborn pigs (Kerner et al. 1984, Baltzell et al. 1987). 
5.2 Materials & Methods 
5.2.1 Animals 
Newborn, colostrum-deprived piglets (n~2l, avg. weight 1.29±0.1 kg) were removed from 
their dams at birth and deprived of food. Via a minor surgical procedure, two arterial catheters 
were inserted into the animals via the umbilical arteries, and a bladder catheter was inserted via 
the urachus. The animal protocol for this research was approved by the University of Illinois 
Laboratory Animal Care Advisory Committee and was in accordance with the "Guide for the 
Care and Use of Laboratory Animals". 
The surgical procedure used to insert the catheters was as follows. Piglets were sedated using 
isoflurane (2%, Anaquest, Madison, WI) as a general anesthesia; and in addition, a local, 
subcutaneous lidocaine injection (3 mg; Anthony Products, Arcadia, CA) was administered. 
Subsequently, the umbilicus was cut off approximately 1 cm above the body wall (in the region 
where the tissue is atrophic). This exposes the umbilical arteries and vein (the arteries are smaller 
in diameter and have a less apparent lumen). The lumen in the artery was opened using curved 
watchmaker forceps and a catheter introducer (Becton Dickenson, Rutherford, NJ) and a catheter 
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(argyle umbilical catheter, 3% French, Sherwood Medical, St. Louis, MO) was inserted. This 
catheter was threaded (approximately 22 cm for the blood sampling catheter) via the external ileac, 
cranially up the abdominal artery into the abdominal aorta (verified by X-ray photography). To 
facilitate insertion of the catheter, the umbilicus was raised slightly (ventrally) and pulled craniad 
for the insertion of the arterial catheters. This procedure was repeated for the other artery in which 
the catheter was inserted only 20 cm (infusion catheter). After inserting both arterial catheters, 
the umbilical arteries were pulled apart exposing the urachus (visible as a small, opaque vessel). 
The urachus was subsequently dissected free from umbilical tissue until a wider region of the 
urachus became visible (> 2 mm wide). Using hemostats, the urachus was secured in place, after 
which a small hole was punctured through the wall using a 22 gauge needle. Using a catheter 
introducer, the bladder catheter (urethral catheter, 3% french, Sherwood Medical, modified to 
have 6 holes over the first 7 cm) was subsequently inserted for approximately 9 cm. After insertion, 
the catheter was secured in place by suturing it into the urachus; all catheters were sutured to 
the umbilicus. The incision into the umbilicus was subsequently closed (using sutures), and the 
exterior parts of the catheters were guided to the back of the animal using a suture and tape. 
After recovery from the surgery (1 h), an infusion line was connected to the arterial catheter 
(inserted 20 cm) of each pig and connected to an eight-channel peristaltic infusion pump (model 
07524, Cole Parmer Instrument Co., Niles, IL) which allowed a continuous delivery of infusate 
from i.v. bags (Baxter Healthcare Corp, Deerfield, IL). The other arterial catheter (inserted 22 
cm) was connected to a blood sampling line (flushed with heparinized saline, 5 units/ml). Blood 
was sampled at 0 (before the start of MCFA infusion), 8%, 12%, 16% & 20% h after the start 
of the fatty acid infusion, and at the end of the experiment (24h). Plasma was obtained after 
centrifugation of the blood (at 4°C) and was stored at -20°C until analysis. 
The bladder catheter was connected to a vacuum manifold (which was adjusted to produce 
a vacuum of approximately 70 mbar), via a urine collection vial (16 ml Falcon tube placed in 
ice). Urine was collected quantitatively every hour. To ensure proper collection of the urine, the 
bladder catheters were flushed frequently to verify complete recovery of the flush solution. 
During each of 3 trials, piglets were housed in one of 6 heated (35°C) respiration chambers 
(Kempen & Odle 1993). The chambers were connected to an air inlet containing a sodasorb canister 
to remove incoming C02, and air was pulled through the chambers using a vacuum pump at a 
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rate of 2 L/min (controlled by flow meters, Cole Parmer Instrument, Niles, IL). Air exiting the 
chambers was diffused through a column containing 100 mL of a 1.8 M sodium-hydroxide solution 
to trap expired 14C02. The sodium-hydroxide solution was replaced at sixty-minute intervals during 
which time the air flow was switched to a bypass column for 10 minutes. Preliminary studies 
(Kempen & Odle 1993) verified that under these conditions, in excess of 95% of the expired C02 
was trapped in the NaOH during the collection period. 
5.2.2 Infusion protocol 
The treatments to which the animals were allotted are summarized in Table 5.1. Three animals 
served as the fasted controls (Fasted-ctrl). These animals were submitted to surgery, housed at 
35°C, and fed water during the infusion experiment. The other 18 animals were placed in the 
respiration chambers and were infused for 2 h with physiological saline at a rate of approximately 
10 ml/h in order to maintain the animals in a hydrated state. 
After this adaptation period, an infusion with [l-14C]-octanoate (C8, 20 pCi/24 h, American 
Radiolabeled Chemicals, St. Louis, MO; diluted with non-radioactive C8, Sigma Chemical, St. 
Louis, MO) was started (time 0 h) and maintained for 24 h at a rate estimated to provide between 
35-100% (energy content of C8 calculated to be 4470 kJ/mol) of the metabolic requirements of 
the animal (estimated to be 200 kJ/ (d-kg075), Kempen & Odle 1993). The octanoate infusion 
rate was constant for each animal, but varied between animals. No additional treatments were 
provided to the C8-ctrl animals. 
In addition to the octanoate infusion, pigs alloted to the C8-carn treatment were co-infused 
with L-carnitine (for 8 h) starting 16 h after the start of the octanoate infusion. The carnitine co-
infusion consisted of a prime dose of carnitine (50 junol/kg75) and a continuous infusion of 20 
fcmol/(h-kg0-75), Lonza AG, Ch4002, Basel, Switzerland). The carnitine dose was based on data 
from Kempen & Odle (1993). 
Pigs alloted to the VPA-C8-carn treatment were given, in addition to the octanoate infusion, 
a pulse dose of valproate equivalent to 180 /*moI/kg075 (clinically recommended dose per kg body 
weight per day) two hours before the start of the octanoate infusion. In addition, valproic acid 
was co-infused with octanoate (from 0-24h) at a rate of lOpmol/ kg0-75. Carnitine was co-infused 
to the VPA-C8-carn animals using the same procedure as used for the C8-carn pigs. 
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All infusion solutions were made iso-osmotic (308 mmol/1) using NaCl and thepH was adjusted 
to 7.4. The fluid delivery rate was 15-20 ml/(h-kg). Upon infusion of the fatty acid solution, the 
piglets would generally sleep, but could be aroused easily by moving the chamber. 
Table 5 . 1 . Time course of the infusion regimens to which newborn, colostrum-deprived 
p ig l e t s were a l lo ted to determine the effects of octanoate, valproate, and carni t ine 




* prime dose (50 ^ mol/kg-7S) 
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J ; F a s t e d - c t r l animals were only used for t i s s u e and plasma analys is 
2; The infusion r a t e of CB was constant throughout the 24 h infusion for each animal, 
but var ied between animals. 
After the infusions were completed, pigs were anesthetized using an i.v. injection of pentobarbital 
(30 mg/kg body weight) and euthanized via exsanguination. Samples of the liver and semitendinosus 
muscle were collected, frozen in liquid nitrogen, and stored at -70°C until analysis. 
5.2.3 Sample analysis 
Urinary excretions were quantified (ml/h) and analyzed for dicarboxylic acids using an HPLC 
procedure modified after Rebouche et al. (1990). In brief, 250 pi of urine, after the addition of 
50 nmol of azelaic acid (DC9) as the internal standard, was acidified using 50 pi of 2 N HC1 
and then saturated with NaCl. Dicarboxylic acids were subsequently extracted using ethyl-acetate. 
This extract was evaporated to dryness. Dicarboxylic acids were subsequently derivatized using 
2-bromoacetophenone (2 mg) as the chromophoric reagent and diisopropylethylamine as a catalyst 
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(7 ii\, all reagents were obtained from Sigma, St. Louis, MO, unless noted otherwise) in 400 
lil acetonitrile and 100 fil MeOH. The derivatization was performed using an ultrasonic water 
bath (model 3200, Brandson, Danburry, CT) which was preheated to 60°C. 
The HPLC procedure used a C18 Ultrasphere IP column (250-4.6 mm, Beckman Instruments, 
Palo Alto, CA) and aC18 Absorbosphere HS guard column (Alltech, Deerfield, IL). The column 
was equilibrated with a mixture of 55 % acetonitrile in water, which was maintained until 5 minutes 
after injection of the sample (20 pi). Over a period of 18 min the acetonitrile concentration was 
then increased linearly to 83%, which was maintained for 1 min. The column was subsequently 
re-equilibrated so that injections could be made every 35 minutes. The retention time of DCA 
was determined using standards (Sigma Chemicals, St. Louis, MO). UV absorbance of bromophenacyl 
esters of DCA was monitored at 245 nm, and the concentration of DCA in urine was calculated 
by comparing these peak areas to the peak area of the internal standard, azelaic acid. 
Plasma (150 pi), urine (250 pi, from 1, 6, 11, and 16-24 h), liver (10 mg), and muscle (10 
mg) were analyzed for carnitine esters using an HPLC procedure after Kempen & Odle (1992) 
with minor modifications. Protein was precipitated using a mixture of 75% acetonitrile and 25% 
methanol rather than 100 % methanol. Eluent III (triethylamine-phosphoric acid in 80 % acetonitrile 
and 20% water) was started at 4 min after injection and increased linearly over 26 min to 100%. 
Sodium-hydroxide samples were analyzed for total C02 as described by Benevenga et al. (1992). 
Radioactivity in C02 was determined by mixing 0.5 ml of the sodium hydroxide solution with 
1.5 ml NH4C1 (1 M) and 18 ml scintillation cocktail (Research Products International, Mount 
Prospect, IL) using a Beckman LS6000IC liquid scintillation counter. 
5.2.4 Data analysis 
Based on the ratio of the specific radioactivity of the expired C02 to the specific radioactivity 
of the infused MCFA, an instantaneous fatty acid oxidation rate (FA-OR=MCFA-derived C02/total 
CO2*100) was calculated, assuming that the fate of the [1-14C] carbon represented the fate of all 
carbons within the fatty acid molecule. The measured radioactivity in C02 was not corrected for 
the lag of expiration of C02 due to dilution in the body pool. This results in an underestimation 
of the actual oxidation rates of the infused [l-14C]-octanoate. This inaccuracy does not, however, 
pose a problem for the interpretation of the results which evaluated the relative change in fatty 
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acid oxidation rate elicited by carnitine supplementation. 
The fatty acid oxidation and DCA excretion data obtained during the carnitine-free infusion 
period were fitted to a single pool exponential curve (Statgraphics, STSC, MD) which was determined 
by Benevenga et al. (1992) to accurately model the fatty acid oxidation data: 
FA-OR = A*(l-e-k(t-b)) 
where: FA-OR=fatty acid oxidation rate (%) 
A=asymptotic maximal FA-OR at t=infinity (%) 
k=fractional rate constant (min'1) 
t=time (min) 
to=lag of start of oxidation of MCFA (min) 
To determine the carnitine response, the curve obtained was extrapolated to the carnitine infusion 
period; and the estimated values of MCFA oxidation and DCA excretion were compared with 
the actual data observed. The differences between observed values and estimated values were 
determined (carnitine response), and treatment differences were tested using analysis of variance 
using SAS (Steel & Torrie 1980). 
Plasma and urine carnitine and acetyl-carnitine data were analyzed using the general linear 
models procedure of SAS with time points modelled as repeated measures and with treatment 
(C8-ctrl, C8-carn and VPA-C8-carn) as the main variable and fatty acid infusion rate as a covariate. 
5.3 Results 
The rates of fatty acid oxidation and C02 production are illustrated for one animal in Fig. 
5.1 as an example data set. These data were obtained from a VPA-C8-carn animal. The data from 
all animals are summarized in Fig. 5.2, in which the increase in fatty acid oxidation rate due to 
carnitine supplementation is expressed as a function of the fatty acid oxidation rate. The increase 
in fatty acid oxidation rate (determined using the fatty acid oxidation rate as a covariate) due to 
carnitine was 2.94 (C8-carn animals at a fatty acid oxidation rate of 41.9%) and 4.18 (VPA-C8-carn 
animals at a fatty acid oxidation rate of 40.3 %); both significantly different (p <0.05) compared 
to the controls (decrease of 0.57 at fatty acid oxidation rate of 41.9%). 
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Fig. 5.1. Example graph of the 
fatty acid oxidation rate 
(FAOR=octanoate-derived 
C02/total CO2*100) and the C02 
production as a function of 
time for a VPA-C8-carn pig 
(see table 5.1). The squares 
represent the measured values 
of FAOR while the solid line 
is the curve as fitted to the 
FAOR of 0-16 h; the dashed 
line is the extrapolation of 
this curve. The FAOR deviated 
(p<0.05) from the extrapolated 





















10 20 30 40 50 60 
Fatty acid oxidation rate (% of MR) 
70 
Fig. 5 .2 . The carni t ine 
response expressed as a l inear 
function of the f a t ty acid 
oxidat ion r a t e . The carni t ine 
response was calcula ted as the 
difference between the octa-
noate oxidation r a t e (FA-OR) 
from 16-24 h and the curve ex-
t rapo la ted from 0-16 h. Each 
point represents the average 
increase in FA-OR from 16-24 
h as ca lcu la ted from data of 
one p ig . Data from CB-ctrl 
p igs were not included in the 
ca l cu l a t ion of the regression 
equation which was (0.16- [FAOR 
-18] (r= 0.73)) . 
The percentage of fatty acid infused which was oxidized to C02 under steady state conditions 
(by extrapolation of the single pool exponential curve) was not affected by valproate coinfusion 
(p=0.11), although it tended to be lower (53.8±1.6% versus 56.6±1.2%) for the VPA-C8-carn 
pigs compared to the C8-ctrl and C8-carn (data from C8-ctrl and C8-carn pigs was combined 
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since both groups underwent the same treatment up to 16 h). The oxidation rates as a function 
of the fatty acids infusion rates are summarized in Fig. 5.3. Oxidation of fatty acids infused, 
independent of the rate of infusion, accounted for 55.6±1% (^=0.995) of the fate of carbon 
for the fatty acids infused. 
Fig. 5.3. The asymptotic 
maximal fatty acid oxidation 
rate of octanoate in newborn, 
colostrum-deprived piglets as 
a linear function of the infu-
sion rate, both expressed as 
energy equivalents as a 
percentage of the metabolic 
rate (MR) of the recipient. 
55.6±1% of the fatty acids 
infused at steady state were 
oxidized to C02 in the absence 
of supplemental carnitine 
w0 25 50 75 100 125 ( r 2 =0 .995) , independent of t h e 
Infusion rate (% of MR) r a t e of infusion. 
The data from the suberic acid (DC8) excretion in urine from 2 animals (C8-ctrl versus VPA-C8-
carn) and the difference between the observed and estimated (as obtained from the extrapolated 
curve) values of DC8 excretion during the last 8 h of infusion across treatments for all animals 
are summarized in Fig. 5.4. The C8-ctrl animals increased DC8 excretion by 68 % over that predicted 
by extrapolation while C8-carn animals decreased DC8 excretion by 8% (p<0.05 compared to 
controls), and the VPA-C8-carn animals decreased the DC8 excretion by 48% (p<0.05 compared 
to C8-ctrl & C8-carn). 
The relationship between suberic acid and sebacic acid (nmol/h) excretion (adipic acid was 
virtually absent in urine) was determined by non-linear regression (based on one group of 6 animals, 
all infused at approximately 100% of their MR; treatments were equally represented) and found 
to be: 
DC10 excretion (nmol/h)=0.117*DC8+0.000086*(DC8)2, r2=0.80, 
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Fig. 5 .4 . Left : example graph of the time course of suberic acid (DC8) excretion 
in two p i g s . Both p i g l e t s were infused with octanoate for a period of 24 h. The 
VPA-C8-carn pig (solid bars) was coinfused with valproate for 24 h and with carni t ine 
during the l a s t 8 h of the experiment. DCS excret ion was determined using HPLC. 
Right: e f fec t of carn i t ine on the suberic acid (DCS) excre t ion . The ca rn i t ine 
response was ca lcu la ted as the r e l a t i v e increase over est imated (extrapolated data 
from 0-16 h) and the observed data for 16-24 h. 
The relationship between the excretion of DC8 in absence of exogenous carnitine and the infusion 
rate of fatty acids was analyzed using nonlinear regression. For this analysis, it was assumed that 
the DC8 excretion from 8-16 hours represented a steady state. The values obtained for the total 
DC8 excretion per day (3*cumulative value for 8-16 h) was compared with the fatty acid infusion 
rate (expressed in mmol/d). The relationships between the fatty acid infusion rate (in mmol/d) 
and DC8 excretion (in nmol/d) were determined to be: 
C8-ctrl & C8-carn : DC8 = 5.52(±0.68) * (C8 infusion)2 (r2=0.92) 
VPA-C8-carn : DC8 = 9.74(±1.48) * (C8 infusion)2 (^=0.87), 
where C8 infusion is in mmol/d, and DC8 (suberic acid) excretion is in nmol/d. 
Both equations were significant (p<0.05), and the excretion of DC8 in the VPA-C8-carn pigs 
was significantly higher (p<0.05) than the DCS excretion in pigs only infused with octanoate. 
The plasma carnitine and acetyl-carnitine concentrations for all animals are summarized in 
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Fig. 5.5, while the urinary carnitine and acetyl-carnitine excretion are summarized in Fig. 5.6. 
Prior to octanoate infusion (0 h samples), plasma acetyl-carnitine was 1.7± .8 pM; and free carnitine 
was 24+6 pM, suggesting a borderline carnitine deficiency (defined as a free carnitine concentration 
of less than 20 pM, Winter et al. 1987) as expected in newborn piglets (Kerner et al. 1984). 
Both plasma carnitine and acetyl-carnitine concentrations increased significantly (7 resp 11 
fold) upon carnitine supplementation (p < 0.05), but no significant differences were observed between 
C8-carn and C8-VPA-carn. In addition, plasma acetyl-carnitine concentrations were significantly 
correlated with the fatty acid infusion rate (see Fig. 5.8), being higher (p <0.05) at high infusion 















Fig. 5.5. Least square means 
(+ standard error of the mean) 
of plasma carnitine (top) and 
acetyl-carnitine (bottom) 
concentrations. Treatments are 
as shown in table 5.1. Average 
values (/zM) for plasma free 
and acetyl-carnitine for 16-24 
h were, respectively,- CB-ctrl, 
21.7 and 2.1; CB-carn, 146 and 
23.6; VPA-CB-carn, 166 and 
22.6. Carnitine esters were 
determined using HPLC. 
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2,500 Fig. 5.6. Least square means 
(+ standard error of the mean; 
determined within treatments) 
of urinary carnitine excretion 
(top) and acetyl-carnitine 
(bottom) excretion. Treatments 
are as shown in table 5.1. 
Average values for urinary 
free and acetyl-carnitine 
excretion (nmol/h) for 16-24 
h were, respectively; CB-ctrl, 
196 and 23; CB-carn, 919 and 
1398; VPA-CB-carn, 334 and 
420. Carnitine esters were 
determined using HPLC. 
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The carnitine esters in urine were mainly free and acetyl-carnitine. Carnitine supplementation 
increased carnitine and acetyl-carnitine excretion in C8-carn pigs (P<0.05), but not in the 
VPA-C8-carn pigs as compared with the C8-ctrl pigs. Other carnitine esters detected had retention 
times corresponding to: propionyl, butyryl, hexanoyl, octanoyl, and valproyl-carnitine (verified 
to be carnitine esters by radioisotopic carnitine exchange using carnitine acetyl-transferase and 
14C-carnitine). The concentration of these esters was, using the sample preparation procedure as 
described, not sufficient to allow for consistent quantification. 
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Liver carnitine (Fig. 5.7) and acetyl-carnitine (Fig. 5.8) concentrations (nmol/g wet weight) 
were not affected by the infusion rates used, but the carnitine-supplemented pigs had significantly 
elevated carnitine and acetyl-carnitine levels (p <0.05). No differences were observed (p > 0.10) 
in carnitine and acetyl-carnitine concentrations (nmol/g) between the C8-ctrl (194 resp. 1.68) 
and Fasted-ctrl group (119 resp. 0.9), and between the VPA-C8-carn (558 resp. 80) and C8-carn 


























•Fasted-ctrl ±C8-cntrl •C8-carn •VPA-CS-cam 
•Fasted-ctrl AC8-cntrl •C8-carn "VPA-CS-carn 
0 20 40 60 80 100 120 
Fatty acid infusion rate (% of MR) 
Fig. 5.7. Carnitine concentra-
tion (nmol/g wet weight, 
average value for 16-24 h) in 
plasma, liver, and muscle 
(semitendinosus) as affected 
by the fatty acid infusion 
rate (FAIR=energy infused as 
a percentage of the metabolic 
rate of the recipient) and 
treatment (see table 5.1) . The 
regression line as depicted 
for muscle carnitine are based 
on data from CB-carn & VPA-CB-
carn animals and is as fol-
lows: 188 + 7.2*FAIR (r2=0.49, 
p<0.05) . Carnitine was deter-
mined using HPLC. 
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Muscle carnitine concentrations were affected by both carnitine supplementation and the fatty 
acid infusion rate (see Fig. 5.7). Carnitine supplementation increased muscle carnitine almost 
two fold (from 493 to 873 nmol/g). 
Muscle acetyl-carnitine levels were affected by the fatty acid infusion rate (see Fig. 5.8, p=0.051), 
but not by carnitine supplementation (non-supplemented pigs: 109 nmol/g versus supplemented 
pigs: 165 nmol/g, p>0.10). 
35, • Fig. 5.8. Acetyl-carnitine 
" - / ^ concentration (nmol/g wet 
oO -^« 
weight, average value from 16-
24 h) in plasma, liver, and 
muscle (s emitendinosus) as 
affected by the fatty acid 
infusion rate (FAIR=energy 
infused as a percentage of the 
metabolic rate of the recipi-
ent) and treatment (see table 
5.1) . The regression lines as 
depicted are based on data 
from CB-carn & VPA-CB-carn 
animals and are as follows: 
Plasma: 4.5+0.24*FAIR (r2 = 
0.57, p<0.05) 
Liver: -1.9+1.2*FAIR (r2 = 
. 1 9 , p=0.12) 
Muscle : 81+1.3*FAIR ( r 2 = . 2 4 , 
p=0.051) 
A c e t y l - c a r n i t i n e was d e t e r -
mined u s i n g HPLC. 
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5.4 Discussion 
Carnitine supplementation caused a similar increase in medium-chain fatty acid oxidation rates 
(see Fig. 5.2) as determined in a previous experiment (this experiment: 0.16-[fatty acid oxidation 
rate-18] versus 0.18*[fatty acid ox rate-20], Kempen & Odle 1993). This confirms that carnitine 
does stimulate octanoate oxidation in vivo when the fatty acid oxidation rate exceeds approximately 
20% of the metabolic requirements of the animal, and furthermore, that the stimulatory effect 
of carnitine increases with increasing rate of fatty acid oxidation. 
Fatty acid oxidation accounted for 55.6% of the fate for the fatty acids infused (see Fig. 5.3) 
under steady state condition. This value is higher than what was found in previous research (40 %, 
Kempen & Odle 1993) but is in agreement with data from Odle et al.(1992). The reason for this 
difference is not clear. For a discussion regarding the fate of the remaining carbon, see Kempen 
& Odle (1993) and Odle et al. (1993). 
Octanoate competitively inhibitits the activation of valproate (Becker & Harris 1983, Draye 
& Vamecq 1987), since the affinity of the medium-chain acyl-CoA synthetase enzyme, which 
is required for the activation of valproic acid, is several fold higher for octanoate than for valproate 
(Draye et al. 1988). To avoid the inhibition of valproate activation, we infused a large (180 
/imol/kg075) dose of valproate 2 h before the start of the octanoate infusion. Even though valproate 
was infused before octanoate, the valproate treatment did not significantly affect fatty acid oxidation. 
The lack of an inhibitory response to valproate in fatty acid oxidation contrasts with in vitro data 
reported by Bjorge et al. (Bjorge & Baillie 1985) and Ponchaut et al. (Ponchout et al. 1992), who 
showed decreases in C10 oxidation with valproate treated rat liver homogenates. 
The suberic acid excretion increased due to the fatty acid infusion and increased even further 
(76%) in piglets infused with valproate. This suggests that valproate did have an inhibitory effect 
on fatty acid oxidation, resulting in a higher intracellular fatty acid concentration, and thus a higher 
production of DC8. If the action of valproate is limited to the liver, the only tissue with an 
intramitochondrial medium-chain acyl-CoA synthetase (Groot & Hulsmann 1973, Groot et al. 
1976), then the lack of a response of valproate on fatty acid oxidation might simply be caused 
by a "dilution" effect. If the fatty acid oxidation rate in other tissues was unaltered (or even increased; 
muscle acetyl-carnitine, which was positively correlated with the fatty acid infusion and thus oxidation 
rate, was elevated in VPA-C8-carn (p=0.06) but not in C8-carn as compared to C8-ctrl pigs), 
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inhibition of liver fatty acid oxidation might have gone unnoticed under the conditions employed. 
Suberic acid excretion was decreased after carnitine supplementation as compared to C8-ctrls. 
The decrease was larger in the VPA-C8-carn animals (p<0.05). Surprisingly, after carnitine infusion, 
the DC8 production (5.08 versus 5.06 *fatty acid infusion2) as well as the fatty acid oxidation 
rates (61.1% versus 61.0%) were identical in both treatment groups (VPA-C8-carn versus C8-carn). 
The decrease in DCA excretion as observed after carnitine supplementation is in agreement with 
clinical observations that DC8 excretion is lowered after carnitine supplementation (Olson & Nelson 
1989, Whyte et al. 1986). The role of carnitine in lowering DC8 excretion might be mediated 
via increasing the oxidation of octanoate, and therefore decreasing the intracellular concentration 
of octanoate in liver. (Olson & Nelson (1989) showed a decrease of plasma free fatty acid concentra-
tion in infants after carnitine supplementation.) Since the conversion of octanoate to DC8 is 
concentration dependent, a lower intracellular concentration of octanoate could potentially explain 
(a portion of) the lower excretion rate of DC8. 
The dicarboxylic acid excretion in control animals did not reach a steady state during the 24 
h infusion, as indicated by the increase in DC8 excretion during the last 8 h of the experiment 
versus the modelled data in C8-ctrl animals. This is surprising since the fatty acid oxidation rate 
did approach a steady state after approximately 8 h of octanoate infusion. A steady state fatty 
acid oxidation rate in our study implies also a steady state systemic fatty acid concentration since 
the maximum fatty acid oxidation rate was not imposed by metabolic limits, but rather by the 
fatty acid infusion rate. It is possible that the observed increase in DC8 excretion represents an 
adaptation mechanism to the continuous fatty acid load (Hare & Wahle (1985) showed an increased 
capacity for w-oxidation in sheep after a fast). 
The conversion rate of fatty acids infused to dicarboxylic acids excreted (which is not based 
on steady state conditions), was approximately 5 fold lower that what has been reported in vitro 
(Mortensen & Gregersen 1981). However, the average conversion rate as observed in this study 
(in the non-valproate infused animals) was 0.021 ±0.0034% of fatty acids infused, which was 
similar to the values as observed by Mortensen & Gregersen (1981) and Mortensen (1992) in 
vivo, who reported values of 0.019-0.030% and confirms that w-oxidation is quantitatively not 
a major pathway. 
The mechanism of action for carnitine on in vivo octanoate oxidation is still open for debate. 
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Observations in this experiment are that carnitine causes an increase in octanoate oxidation and 
a decrease in DC8 excretion. The effect of carnitine on octanoate oxidation has been suggested 
to be via its action on muscle tissue, where octanoate oxidation is carnitine dependent (Groot & 
Hulsmann 1973). It is, however, unlikely that muscle carnitine was limiting B-oxidation since 
the levels measured in the non-carnitine supplemented animals (493 nmol/g) were similar to liver 
carnitine after carnitine supplementation (540 nmol/g, which is the normal range as reported by 
Shenai et al. 1983) and high as compared to unsupplemented livers (194 nmol/g), while rates 
of 8-oxidation in liver far exceed those of muscle per unit of weight (Ernster & Nordenbrand 
1967). Indeed, Watmough et al. (1988) reported that the maximal C02 production in isolated muscle 
mitochondria was achieved in an environment containing 100 pM carnitine. 
Tissue analysis revealed that the concentration of acetyl-carnitine in muscle was independent 
of carnitine supplementation, but rather correlated with the fatty acid infusion rate. It is possible 
that acetyl-carnitine was formed by peroxisomal 8-oxidation (Vamecq & Draye 1987) and functions 
in the transfer of acetyl units from peroxisomes to mitochondria within the cell. The muscle acetyl-
carnitine does not appear to diffuse into plasma, since, as shown in Fig. 5.8, muscle acetyl-carnitine 
in non-carnitine supplemented pigs was 70% of that in carnitine supplemented animals while plasma 
acetyl-carnitine did not increase and urinary acetyl-carnitine remained virtually non-detectable 
in the C8-ctrl pigs. 
The increase in plasma acetyl-carnitine did, however, mirror the liver carnitine profile (Fig. 
5.8). Liver acetyl-carnitine increased 50 to 60-fold upon carnitine supplementation, suggesting 
that the liver is the source of plasma and urinary acetyl-carnitine. The effects of carnitine on liver 
fatty acid oxidation could be mediated via the carnitine-dependent transport of medium-chain fatty 
acids into the mitochondria, potentially due to insufficient activation of medium-chain fatty acids 
by intramitochondrial medium-chain acyl-CoA synthetase as suggested by Stanley etal. (1983), 
which would make (a portion of) octanoate oxidation carnitine dependent. This would decrease 
the cytosolic fatty acid concentration by enhancing oxidation, and thus, decrease dicarboxylic 
acid production. Although the data are consistent with this notion, there appears to be a lower 
limit for fatty acid oxidation below which carnitine does not have any stimulatory effects. This 
might be explained by some baseline levels of carnitine in tissues but also by the broader chain-length 
specificity of the intramitochondrial short-chain acyl-CoA synthetases, as the name implies. Since 
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sufficient active intramitochondrial short-chain acyl-CoA synthetase is present at birth and since 
this short-chain acyl-CoA synthetase has some affinity for C8, low levels of C8 oxidation could 
occur in the absence of carnitine (Groot et al. 1976, Aas 1971). 
Alternatively, carnitine could have a role in mediating the excess acetyl-CoA formed during 
uncontrolled 8-oxidation of medium-chain fatty acids. Since our model species, the piglet, lacks 
sufficient ketogenic capacity (Adams & Odle 1993), excess acetyl-CoA formed (or lack of free 
CoA) is not detoxified (free CoA is not regenerated) via this pathway. Carnitine could potentially 
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Concluding remarks 
Does carnitine have a role in medium-chain fatty acid metabolism? 
The primary objective of the research presented in this thesis was to determine whether carnitine 
has a role in the oxidation of medium-chain fatty acids (MCFA) in our model species, the pig. 
From the data as presented, I would conclude that carnitine indeed has a role. However, the exact 
mechanism of this role and whether this role of carnitine is the same in other species and/or older 
pigs has not been not answered. 
The newborn piglet is unique in several ways. First, the newborn pig does not make ketone 
bodies at rates comparable to other (ketogenic) species (Adams & Odle, 1993). This "metabolic 
disorder" may have several implications. Due to the absence of ketogenesis, 8-oxidation has the 
potential to occur at a rate which exceeds the liver's capacity to metabolize the acetyl-CoA formed. 
This potential increases when MCFA are fed or infused, since their metabolism bypasses the regula-
tory site of 8-oxidation (carnitine palmitoyl transferase I). The newborn pig is, therefore, at risk 
for depleting intramitochondrial free CoA when MCFA are fed. Carnitine has the potential to 
counteract this depletion, and thus, improve the metabolic health of the subject (see Chapter 5). 
A second, possible idiosyncrasy might be the age of the animals used. Several researchers 
(Shipp et al. 1982, Stanley et al. 1983) have shown that newborn guinea pigs lack intramitochondrial 
acyl-CoA synthetase activity. However, no data on medium-chain acyl-CoA synthetase activity 
and development after birth is available for other species. 
The lack of (active) medium-chain acyl-CoA synthetase would render the activation of MCFA 
dependent on intramitochondrial short-chain acyl-CoA synthetases and extra-mitochondrial (not 
at the site of 8-oxidation) acyl-CoA synthetases. Since the affinity of the intramitochondrial short-chain 
acyl-CoA synthetase is low for medium-chain fatty acids such as octanoate, a substantial amount 
of the MCFA would be activated extramitochondrially. These extramitochondrially activated MCFA 
are oxidized in a carnitine-dependent fashion (Groot & Hulsmann, 1973). The effect of carnitine 
under these conditions is dependent upon the capacity of the intramitochondrial acyl-CoA synthetase; 
if it can meet the requirements of the mitochondrion for activated fatty acids, then the carnitine 
dependent uptake of fatty acids is inhibited, alleviating the role of carnitine. It is more likely, 
however, that the capacity of the intramitochondrial short-chain acyl-CoA synthetase is not sufficient 
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to meet the cell's requirement for activated fatty acids, suggesting that MCFA oxidation would 
be carnitine dependent. 
If none of these idiosyncrasies caused the effects observed, then carnitine will likely have a 
role in MCFA oxidation in several species. Currently, we do not know the answer to these questions. 
Neonatal survival 
As noted in the introduction, the focus of the research in our laboratory is to improve neonatal 
survival in commercial swine operations. The question addressed in this thesis is beyond the original 
focus of our lab, although the outcome may have some impact on neonatal survival. I think that 
it is recommendable to fortify a "neonatal survival kit" containing MCFA, with carnitine. 
In addition to the role of carnitine in MCFA metabolism, several other observations are worth 
mentioning in light of the original focus of our laboratory. 
During the first chamber studies, it was discovered that MCFA can be toxic when infused 
at rates exceeding 400 kJ/(d-kg0-75). Toxicity of MCFA has been observed by other researchers 
who used large, extra-nutritional doses; but intoxication is not considered a risk factor when MCFA 
are fed to, e.g., infants and pigs. Obviously, this risk should be reconsidered, as we learned in 
infusion trials, and later through feeding trials. (This risk might, however, be limited to non-ketogenic 
species). 
In the same chamber studies, it was also noticed that the metabolic rate of newborn, colostrum-
deprived pigs was significantly lower (60%) than what it was estimated to be by Noblet & Le 
Dividich (1981) and Le Dividich & Noblet (1984). Piglets are born with a metabolic rate only 
slightly higher than the dam's metabolic rate, which, due to the large difference in weight, is 
substantially lower (per kg body weight) than that of an average 1-2 kg mammal (Mellor & Cockburn, 
1986). 
The metabolic rate of newborn piglets is not increased by MCFA infusion (or feeding), which 
contradicts the assumption that MCFA are a thermogenic, obligatory fuel. This also means that 
the low metabolic rate of the piglet is not determined by a lack of fuel, since an excess of MCFA 
was provided and the oxidation of these MCFA reached up to 80% of the total metabolic requirement 
of the animal. If the piglet indeed has such a low metabolic rate, then the hypothesis that the metabolic 
rate of an animal is determined by its surface area can not be correct (Kleiber, 1975). Several 
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days after birth; these piglets do have a "normal" metabolic rate - twice what it was at birth, but 
their relative surface area did not change. It seems more plausible that the surface area of an animal 
would be determined by its adaptation to the environment. 
Medium-chain fatty acids are unable to increase the heat production of animals. So how useful 
are MCFA as a nutritional supplement to improve survival? Since MCFA spare body stores, they 
can probably extend the life of the piglet. However, in a production environment the piglet will 
have several litter mates which will start suckling immediately after birth. These animals are growing 
and will increase their metabolic rate to a normal range within 2 days of life. Although the MCFA-
supplemented pig can live longer, it is not better able to maintain his body temperature, and thus, 
compete with its larger litter mates. So, it is not likely that the fate of the MCFA-fed newborn 
pig has changed. 
To improve piglet survival, the provision of only fat as an energy source is not sufficient. 
Instead, a substrate which stimulates the intestines to start functioning should be fed such that 
the piglet increases his heat production. In addition, energy should be provided which enables 
the piglet to maintain a higher heat production for a sufficient length of time; this will enable 
the piglet to start suckling. One possible avenue for future research might be to use a mixture 
of non-emulsified medium-chain triglycerides (containing butyrate and heptanoate as an energy 
source), proteins (such as casein and immunoglobulins to stimulate the digestive tract), and some 
caffeine (to raise the animals' heat production). In addition to proper nutrition, it is of major 
importance to provide the piglet with a (temporary) environment which will protect the piglet 
from excessive heat loss, or even increase the body temperature of the pig using, for example, 
microwave energy (Braithwaite et al. 1989). 
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Appendix A. Peroxisomes 
Peroxisomes were discovered in 1954 by Rhodin. They are organelles with a single, easily 
permeable cell membrane, loaded with enzymes in a crystalline fashion (catalase). Their size varies 
considerably, from .2 to 5 pm and they form from budding (incompletely) off of the smooth 
endoplasmic reticulum with which they will still maintain channel-like contacts. The original role 
of peroxisomes was thought to be the detoxification of oxygen. The environment used to have 
a very low oxygen tension. When oxygen started to build up, organisms had to deal with oxygen 
as a toxic agent. Peroxisomes are capable of capturing oxygen, and making hydrogen peroxide 
out of it as follows: 02 (oxidase, e.g. flavoproteins) -»H202 (catalase + O2)-^2H2O. The functions 
of peroxisomes in an oxygen dependent fashion, however, are not well understood (De Duve 1982). 
Several mechanisms have been developed to study the peroxisomes. One of the most common 
used ones is the study of isolated peroxisomes. Peroxisomes are most often isolated by gradient 
centrifugation. Due to the very similar densities of mitochondria, lysosomes and peroxisomes, 
classical centrifugation turned out to be ineffective. The density of lysosymes can be altered by 
feeding the subject a non-ionic detergent, like Triton X-100 or Triton WR-1339. These compounds 
are absorbed by the lysosomes, and alter their density. Separation from the mitochondria is less 
easy. After gradient centrifugation for several hours, sufficient separation can be achieved. However, 
some mitochondrial contamination will remain present (Vamecq & Draye 1989). 
To avoid isolation, specific reactions of the peroxisomes have been studied, like hydrogen 
peroxide formation (inhibiting catalase). The disadvantage of this system are several, including 
the disruption of normal processes, the lack of knowledge about the breakdown of hydrogen peroxide, 
and the damage done by accumulating hydrogen peroxide to normal cell functioning. Most studies 
employ mitochondrial inhibitors, like malonate, cyanide, rotenone or antimycin, or peroxisomal 
stimulators, like clofibrate or ciprofibrate (Vamecq & Draye 1989). Questions can be raised on 
the extrapolation of these results to in vivo because of their dramatic disruption of cell function, 
and of their side-effects (such as NAD depletion). 
In 1976, Lazarow and de Duve discovered a 8-oxidation.system in the peroxisomes. They 
reported 3 enzymes, 2 of which similar to the ones in the mitochondria, and a bifunctional enzyme 
(De Duve 1982). The role of peroxisomal 8-oxidation is chain shortening. The current concept 
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is, that very-long-chain fatty acids (LCFA) and unsaturated fatty acids are taken up by the peroxi-
somes. There they will undergo several cycles of 8-oxidation. The reaction products are then a 
medium-chain fatty acid, acetyl groups, NADH (possibly used to form hydrogen peroxide) and 
hydrogen peroxide. This is summarized in the reaction scheme as depicted in Fig. A.l from Mannaerts 
& de Beer (1982). 
Long-chain fatty acids 
r Endoplasmic reticulum 
' V Mitochondria 
Long-Chain fatty acids acyt-CoA CoA/hexonoyl-CoA 
V CoA / 
ATP-(j*Canie72) 
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Fig. A . l . Peroxisomal 8-oxi-
dat ion (see tex t for d e t a i l s ; 
Mannaerts & de Beer 1982) 




•' lipid synthesis 
The current hypothesis is, that fatty acids undergoing peroxisomal 8-oxidation are activated 
by acyl-CoA synthetase: FA + CoA (+ATP-Mg++) > Acyl-CoA (the use of ATP makes the 
peroxisomes ATP dependent, and might increase their action in a way opposite to the mitochondria). 
This activation can happen after entry of fatty acids into the peroxisomes, or, more likely, upon 
entry into the peroxisomes (Mannaerts & de Beer 1982). 
Three enzymes are involved in peroxisomal 8-oxidation: acyl-CoA oxidase, enoyl-CoAhydra-
tase/8-hydroxy acyl-CoA dehydrogenase and 8-ketothiolase. The end products of peroxisomal 
8-oxidation are acetyl-CoA (or acetate or acetyl-carnitine), medium-chain fatty acids (MCFA) 
and H20. The role of this pathway is unknown. It makes LCFA more polar, and maybe a more 
preferable substrate for the mitochondria (Mannaerts & de Beer 1982). 
The 8-oxidation in the peroxisomes is not coupled to the synthesis of energy-rich phosphate 
bonds. The released electrons are captured in molecular oxygen, forming hydrogen peroxide. 
This hydrogen peroxide is broken down to water and oxygen. The result is a loss of energy but 
an increase in heat production. NADH which is produced might be transported to the cytosol, 
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and be involved in synthesis processes or can be converted to H202 and NAD. Detailed information 
is missing. 
After the acyl-CoA undergo some cycles of 8-oxidation, the resulting acetyl groups and the 
MCFA (decreasing affinity of enzyme for complex) will exit the peroxisome, making them available 
for the mitochondria, or for lipogenic processes/cholesterol synthesis. Within the peroxisomes, 
the CoA can be dissociated by an acyl-CoA hydrolase. Carnitine octanoyltransferase (specifity 
C6, activity towards C4-C16) has a function in the export of these compounds into the cytosol, 
and maybe in the uptake of these compounds by the mitochondria. Carnitine is supposedly not 
involved in uptake of the fatty acids into the peroxisomes. 
The role of peroxisomes in fatty acid metabolism is not quantified very well. Vamecq & Draye 
(1989) assume that the majority of the LCFA are shortened in the peroxisomes to MCFA and 
acetyl-groups. Mannaerts & de Beer (1982) estimates that 2 to 30 percent of the acetyl groups 
is released in the peroxisomes. The number and the activity of peroxisomes can be stimulated 
by high fat diets, and certain drugs like clofibrate. After stimulation, the peroxisomes can be 
responsible for up to 50% of the 8-oxidation (Cannon et al. 1982). 
The loss of energy in the case of palmitate due to peroxisomal oxidation is 2-5 ATPs per 8-
oxidation cycle. The total loss is dependent on the number of 8-oxidations taking place, and if 
the endproduct requires activation. Estimates range from 1 to 4 cycles of peroxisomal 8-oxidation 
per fatty acid molecule, which translates into a loss of 2 to 28 ATP (total ATP yield from palmitate 
oxidation in mitochondria is 129). 
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Appendix B. Effect of infusion of medium-chain fatty acids of varying chain-length on 
dicarboxylic acid (DCA) excretion in newborn, colostrum-deprived piglets 
Introduction 
One of the problems associated with feeding medium-chain triglycerides is the associated 
production of dicarboxylic acids. Medium-chain triglyceride formulas are, however, not formulated 
to minimize the excretion of dicarboxylic acids. The experiment as described herein was designed 
to determine the effect of the chain length of medium-chain fatty acids (MCFA) on the excretion 
of dicarboxylic acids in urine. 
Materials & methods 
The experimental procedure used was similar to that described in Chapter 4 and 5. In brief 
(including the deviations from the protocols described previously), piglets were infused for a period 
of 12 h with either C7 (hexanoate, 2 animals), C8 (octanoate, 1 animal) or CIO (decanoate, 1 
animal) at a rate to provide approximately 60% of the anticipated metabolic rate of the animals. 
Urine was collected quantitatively and analyzed for DCA using HPLC as described in Chapter 
5. 
Results 
We experienced unforeseen problems with the infusion of CIO. Animals infused with CIO 
had severe hemolysis leading to hemoglobinuria. Infusing CIO at lower rates (down to 30% of 
metabolic rate) did not prevent this problem. Due to the severe health problems we decided not 
to continue this line of investigation. Some of the results obtained are summarized below. 
Infusion of CIO resulted in a 6 fold increase in total dicarboxylic acid excretion compared 
to C8. Octanoate infusion resulted in a 2-fold higher DCA excretion than C7. In addition, the 
chain-length of the DCA excreted was predominantly equal to the chain-length of the fatty acid 
infused when CIO or C8 were infused (see Fig. B. 1). When, however, C7 was infused, the excretion 
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Discussion 
Both the chain length as well as the infusion rate of the MCFA greatly affected the excretion 
rate and the excretion pattern of DCA in urine. Our data is in agreement with data from Gregersen 
(1983) and Mortensen & Gregersen (1981) which suggest that both C8 and C7 results in lower 
excretion of DCA than CIO. 
The observation that infusing C7 results in the excretion of DC6 at rates greater than DC7 
implies that not the C7 itself but endogenous long-chain fatty acids are the main substrates for 
omega-oxidation as suggested by Gregerson (Gregersen etal. 1983), which would be in accordance 
with the chain-length specificity of the enzymes involved (Vamecq & Draye 1989). The absence 
of DC6 when C8 or CIO is fed suggests that DC6 is utilized by piglet under those circumstances 
to yield succinate. C7 upon 8-oxidation yields propionyl-CoA which can be converted to succinyl-
CoA. This excess of TCA cycle intermediates produced during C7 oxidation could potentially 
lead to the accumulation of DC6 (Rusoff et al. 1960). 
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